Stockwinners Market Radar for November 30, 2021 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:14 EST Cathie Wood's ARK Investment bought 837K shares of Robinhood on Tuesday

20:10 EST Cathie Wood's ARK Investment bought 162K shares of Zoom Video on Tuesday

18:43 EST Community Financial raises dividend 17% to 17.5c - The Community Financial , the bank holding company for Community Bank of the Chesapeake, announced that its Board of Directors has declared a quarterly cash dividend of 17.5c per share of common stock, up from 15c in the previous quarter. This represents a 17% increase over the previous quarter. The dividend will be paid on or about January 24, 2022 to stockholders of record as of the close of business on January 10, 2022.

18:21 EST Salesforce co-CEO Benioff: I'm never leaving the company - In an interview on CNBC's Mad Money, Marc Benioff said, "I love Salesforce and I'm never leaving. It's my life's pursuit." The core of the business is growing very quickly, faster than expected, he noted. "We're very excited about the future." Co-CEO Bret Taylor said the core of Salesforce's business has "never been stronger."

17:53 EST Merck says FDA panel vote on COVID antiviral a 'positive outcome' - Merck and Ridgeback Biotherapeutics provided a statement at the conclusion of the U.S. Food and Drug Administration's Antimicrobial Drugs Advisory Committee regarding the Emergency Use Authorization application for molnupiravir, an investigational oral antiviral medicine, for the treatment of mild to moderate COVID-19 in adults with positive results of direct SARS-CoV-2 viral testing who are at high risk for progressing to severe COVID-19 and/or hospitalization. The Advisory Committee voted 13-10 that the known and potential benefits of molnupiravir outweigh its known and potential risks for the treatment of mild to moderate COVID-19 in high risk adult patients who are within five days of symptom onset. The FDA is not bound by the committee's guidance but takes its advice into consideration. "The positive outcome of today's FDA Advisory Committee meeting, following a comprehensive review of molnupiravir, including the compelling data from the MOVe-OUT study demonstrating a significant reduction in hospitalizations and deaths, is a critical step toward bringing this promising oral medicine for COVID-19 to appropriate patients in the U.S. With the continued spread of the virus and the emergence of variants, additional treatments for COVID-19 are urgently needed. That is why we are moving with speed and rigor to pursue authorizations and to accelerate broad global access to this investigational medicine," said Dr. Dean Y. Li, executive vice president and president, Merck Research Laboratories. "We are grateful to the members of the Advisory Committee who reviewed our application, as well as to the patients and investigators who participated in our clinical trials, and we will continue to work with the FDA as the agency completes its review."

17:33 EST CTI BioPharma announces extension of FDA review period for pacritinib NDA - CTI BioPharma announced the FDA has extended the review period for the new drug application, or NDA, for pacritinib for the treatment of adult patients with intermediate or high-risk primary or secondary myelofibrosis, or MF. The Prescription Drug User Fee Act action date has been extended by three months to February 28, 2022. In Q2, the FDA granted priority review for CTI's NDA for patients with myelofibrosis with a PDUFA date of November 30. In the course of product labeling discussions, the FDA requested additional clinical data, which was submitted to the agency on November 24. Earlier, the FDA informed the company that it considers the data submission to constitute a "major amendment" to the NDA and therefore the PDUFA date has been extended by three months to provide additional time for a full review of the submission. At the current time, CTI is not aware of any major deficiencies in the application.

17:26 EST Lockheed Martin awarded $121.03M Navy contract modification - Lockheed Martin was awarded a $121.03M modification to a previously awarded firm-fixed-price, cost-plus-fixed-fee, cost reimbursable contract. This modification exercises an option to procure 35 full-rate production electronic Consolidated Automated Support System, or eCASS, units, associated data, engineering support services, and related equipment, including one genie lift, one test program set development suite, three self-maintenance and test/calibration operational test program sets, four calibration equipment suites/kits, 40 rack rail kits, 41 shore installation kits, 42 ship installation kits, 47 core stations, and 109 mission equipment kits in support of the Navy's AV-8B, C-2, E-2D, EA-6B, EA-18G, E-2, F/A-18A/B/C/D/E/F, H-60R/S, T-45 and V-22 programs and Foreign Military Sales, or FMS, customers. Work will be performed in Orlando, Florida, and is expected to be completed in December 2024. The Naval Air Warfare Center Aircraft Division is the contracting activity.

17:24 EST Raytheon Technologies awarded $447.6M Navy contract modification - Raytheon Technologies was awarded an undefinitized $447.6M not-to-exceed modification to a previously awarded cost-plus-incentive-fee, fixed-price incentive, cost-plus-fixed-fee, cost reimbursable contract. This contract provides for the procurement of recurring sustainment support activities including maintenance of support equipment, common program activities, unique and common base recurring sustainment, repair of repairables, field service representatives, common replenishment spares, conventional take-off and landing/carrier variant F-135 unique maintenance services, and short take-off and landing F-135 unique services in support of the F-35 Lightning II F135 propulsion system for the Air Force, Marine Corps, Navy, Air National Guard, non-Department of Defense, or DOD, participants, and Foreign Military Sales customers. Work is expected to be completed in May 2022. The Naval Air Systems Command is the contracting activity.

17:02 EST McCormick increases quarterly dividend to 37c per share - The board of directors of McCormick declared an increase in the quarterly dividend from 34c to 37c per share on its common stocks, payable January 10, 2022 to shareholders of record December 31. At 37c, the quarterly dividend is double the amount paid in 2014.

16:51 EST Momentus to join MSCI Global Small Cap Indexes - Momentus announced its common stock will be added to the MSCI Global Small Cap Indexes after market close on November 30, 2021. CEO John Rood says: "Momentus has taken significant steps this year toward our goal of providing the space transportation and infrastructure services that we believe will drive the growth of the space economy, and we're looking ahead to an exciting future."

16:44 EST Freshpet CEO buys $200K in common stock - In a regulatory filing, Freshpet disclosed that its CEO William Cyr bought 1.8K shares of common stock on November 26th in a total transaction size of $200K, boosting his stake by about 2%.

16:33 EST Kubient acqui-hires assets, personnel of MediaCrossing - Kubient announced its strategic acqui-hire of certain assets and personnel of privately-held MediaCrossing Inc., a digital advertising agency dedicated to bringing advertising tools, technologies and expertise to brands. As a result of the acquisition, MediaCrossing will operate within Kubient's Managed Services division. "MediaCrossing's mission is to deliver tangible results to our clients with their digital advertising campaigns through innovation and client service," said Michael Kalman, CEO and Founder of MediaCrossing. "By joining Kubient, we're able to better assist our clients in achieving their goals, as we provide them access to supply at scale through Kubient's Audience Marketplace coupled with their fraud prevention solution, KAI. Our organization believes that the future of a successful digital advertising strategy hinges upon a brand's ability to work directly and closely with supply sources, and that is exactly why we combined our capabilities with Kubient's. This is a seminal period in the ad-tech space, and we are confident that joining an innovative company like Kubient will be immediately accretive and greatly increase our value proposition."

16:31 EST Wabash launches next-gen grocery delivery vehicle, secures $10M order - The company states: "Wabash, the innovation leader of engineered solutions for the transportation, logistics and distribution industries, announced the launch of a new light-duty, home delivery refrigerated truck body with the company's patented molded structural composite technology. A large national grocery retailer has placed an initial order over $10M for delivery in the first half of 2022."

16:22 EST Salesforce slips over 5% to below $270 after Q3 results

16:19 EST OppFi reaches facilitated issuance of 2M installment loans - OppFi announced that it has facilitated the issuance of more than two million online installment loans with its OppLoans product. Through the OppFi platform, the OppLoans product uses alternative data to reflect a customer's unique financial situation and facilitates credit access through bank partnerships for consumers whose credit scores exclude them from the traditional financial ecosystem. "The accelerated growth of OppLoans shows that millions of everyday consumers are underserved by the mainstream banking system. By utilizing machine learning technologies, alternative data can unlock credit access for those with less than perfect traditional credit scores," said Jared Kaplan, Chief Executive Officer, OppFi. "This important milestone demonstrates why we believe we are well positioned to continue to grow as a leader to help people rebuild financial health with existing offerings like our OppLoans small dollar unsecured personal loans and future products in development." OppFi facilitated the issuance of its first installment loans in 2012, grew to facilitate the issuance of more than 750,000 loans by 2019, and reached the two million loan issuance milestone this month. As the OppFi platform grows, the company has collected more than seven billion informative data points as part of its AI-powered proprietary scoring algorithm, thereby improving its auto approvals to 58 percent for the most recent quarter.

16:19 EST KKR acquires Vista property from Westcore, terms not disclosed - KKR and Westcore announced that Westcore has sold an approximately 197,000-square-foot industrial warehouse located in Vista, California to KKR. Vista Commerce is located on an all-concrete site and features 14 dock-high doors, six grade-level doors, 27-foot clear height and ample power. The property is 100% leased to a publicly listed healthcare diagnostic testing company. "We are pleased grow our industrial real estate footprint in Southern California with the purchase of this well-located and fully leased industrial distribution property," said Ben Brudney, a Director in the real estate group at KKR who oversees the firm's industrial investments in the United States. CBRE represented Westcore in the sale. Westcore acquired Vista Commerce in early 2020 with assistance from CBRE, who also helped secure the lease to the current tenant. KKR acquired Vista Commerce through its KKR Real Estate Partners Americas III fund.

16:17 EST NY AG says filing a motion to force Amazon safety measures at SI facility - New York Attorney General Letitia James tweeted: "I'm filing a motion to force @amazon to immediately implement #COVID19 safety measures at its Staten Island facility after failing to protect its workers and to reinstate Chris Smalls, who was fired for speaking about these issues. Amazon must stop putting profits over people." Reference Link

16:16 EST Gan Limited board authorizes repurchase of up to $5M in shares - Gan Limited announced that its Board of Directors has authorized a share repurchase program which permits the Company to purchase up to an aggregate of $5 million of its ordinary shares on the NASDAQ Capital Market. Share repurchases under the new authorization may begin immediately and the program will expire on May 31, 2022. The shares will be repurchased with cash on hand and cash from operations. Any shares repurchased will be returned to treasury for cancellation. The price which the Company will pay for any such shares will be the prevailing market price at the time of acquisition, subject to certain limitations imposed by applicable securities laws. The actual timing, manner, and number of shares repurchased under the program will be determined by management at its discretion, together with further discussions with the board, and will depend on several factors, including the market price of GAN's common shares, general market and economic conditions, alternative investment opportunities, and other business considerations in accordance with applicable securities laws and exchange rules. The authorization does not obligate GAN to acquire any particular number of shares and repurchases may be suspended or terminated at any time at GAN's discretion.

16:14 EST Box sees Q4 EPS 22c-23c, consensus 22c - Sees Q4 revenue $227M-$229M, consensus $222.93M.

16:13 EST Box announces $200M expansion of stock buyback program - On November 27, 2021, the Board of Directors authorized an expansion of its stock repurchase program by $200 million of Box's Class A common stock, increasing the aggregate amount of its approved share buyback programs to $700 million, including the Dutch Tender Offer from earlier this year. With this expanded authorization, and excluding funds previously used to repurchase shares to date, as of November 29, 2021, the Company had approximately $260 million of remaining buyback capacity.

16:11 EST Zscaler up 4.3% after reporting Q1 earnings, giving Q2, FY22 guidance

16:09 EST HealthStream announces share buyback authorization for up to $20M - The share repurchase program will terminate on the earlier of November 29, 2022 or when the maximum dollar amount has been expended.

16:07 EST MasterCard raises quarterly dividend to 49c from 44c per share - The cash dividend will be paid on February 9, 2022 to holders of record of its Class A common stock and Class B common stock as of January 7, 2022.

16:07 EST NetApp reports Q2 billings up 7% y/y to $1.55B - Reports Q2: NetApp Public Cloud annualized revenue run rate, or ARR, increased 80% year-over-year to $388M; All-flash array annualized net revenue run rate increased 22% year-over-year to $3.1B; Product revenue grew 9% year-over-year to $814M.

15:52 EST NFL says average viewership of 29.7M for Thanksgiving games 'highest since 1998' - NFL said via Twitter that, "Huge @NFL viewership numbers on Thanksgiving *Avg. viewership of 29.7 million (TV+Digital) for the 3 Thanksgiving Day games -- highest since 1998 *Viewers watched total of 17.1 billion minutes of LIVE @NFL games on Thanksgiving Day -- highest on record." Reference Link

15:49 EST EQT Infrastructure completes acquisition of Covanta - Covanta (CVA) announced the completion of its $5.3B acquisition by the EQT Infrastructure V fund and unveiled its strategy "to become the most sustainable provider of waste solutions." Covanta also announced the appointment of Azeez Mohammed as President and CEO. Mohammed most recently served as Executive Vice President at Bloom Energy (BE).

15:26 EST Longeveron announces Phase 2 Lomecel-B clinical trial in Japan - Longeveron announced that it has entered into a sponsored clinical research agreement with the National Center for Geriatrics and Gerontology and Juntendo University Hospital in Japan, to explore the safety and efficacy of Lomecel-B in older, frail Japanese subjects. "We are excited to embark on this collaboration with the NCGG, one of the top advanced and specialized medical research centers in Japan, and Juntendo University Hospital," said Geoff Green, Chief Executive Officer at Longeveron. "We believe our work could be especially impactful in Japan, which has one of the oldest and fastest aging populations in the world, and where early identification and intervention of frailty is a priority," continued Mr. Green. Lomecel-B has been evaluated in Phase 1 & 2 aging frailty clinical studies in the U.S. In addition, the U.S. Food and Drug Administration recently granted rare pediatric disease designation for Lomecel-B to treat Hypoplastic Left Heart Syndrome, a life-threatening heart condition in infants. A Phase 2 clinical trial is currently underway in babies with HLHS.

15:17 EST Longeveron Inc (Class A Stock) trading halted, volatility trading pause

14:49 EST Merck raises dividend to 69c from 65c per share - Merck announced that the board of directors has declared a quarterly dividend of 69c per share of the company's common stock for the first quarter of 2022. Payment will be made on Jan. 7, 2022 to shareholders of record at the close of business on Dec. 15, 2021. Previously, Merck's board had declared a quarterly dividend of 65c per share of the company's common stock for the fourth quarter of 2021.

14:26 EST Ardelyx announces plans to launch Ibsrela for IBS-C in Q2 of 2022 - Earlier, Ardelyx announced plans to launch Ibsrela, the company's approved treatment for irritable bowel syndrome with constipation, or IBS-C, in adults, in the second quarter of 2022. Mike Raab, president and CEO of Ardelyx, stated, "Over the last five years, the IBS-C market has grown to be sizeable and concentrated, with 9,000 high-writing physicians accounting for approximately 50% of the almost five million prescriptions written annually for drugs indicated for the treatment of IBS-C. This market is ripe for the entry of a novel therapeutic option like Ibsrela, as existing therapies do not adequately address all patient treatment needs. Our market research has clearly shown that treating physicians recognize the need for new therapeutic alternatives to address the unmet medical needs of patients currently managed for IBS-C. That same research demonstrates high interest in, and intent to prescribe, Ibsrela for a subset of patients. By capturing even a modest share, in the mid to high single-digit of this large market, Ibsrela has the potential to generate at least $500 million in peak annual net revenue. We will use the next few months to build commercial inventory and prepare the market for a second-quarter 2022 launch. We believe we have a clear line of sight to breakeven and ultimate profitability for the product, which we expect will create significant shareholder value... "As we work to bring IBSRELA to patients, we remain intent on pursuing approval of tenapanor for hyperphosphatemia through the formal dispute resolution process with the FDA, and as a commercial facing organization, if approved, we will be well-positioned to bring this novel therapy to patients."

14:00 EST AWS announces AWS IoT TwinMaker - On Tuesday, at AWS re:Invent, Amazon Web Services, an Amazon.com (AMZN) company, announced AWS IoT TwinMaker, a new service that "makes it faster and easier for developers to create digital twins of real-world systems like buildings, factories, industrial equipment, and production lines," the company said. Digital twins are virtual representations of physical systems that are regularly updated with real-world data to mimic the structure, state, and behavior of the objects they represent. "AWS IoT TwinMaker makes it easy for developers to integrate data from multiple sources like equipment sensors, video cameras, and business applications, and combines that data to create a knowledge graph that models the real-world environment. With AWS IoT TwinMaker, many more customers can use digital twins to build applications that mirror real-world systems to improve operational efficiency and reduce downtime. There are no up-front commitments or fees to use AWS IoT TwinMaker, and customers only pay for the AWS services used," the company explained. Using AWS IoT TwinMaker, developers can quickly get started building digital twins of devices, equipment, and processes by connecting AWS IoT TwinMaker to data sources like equipment sensors, video feeds, and business applications. AWS IoT TwinMaker contains built-in connectors for AWS IoT SiteWise, Amazon Kinesis Video Streams, and Amazon S3 to make it easy to gather data from a variety of sources. AWS IoT TwinMaker automatically creates a knowledge graph that combines and understands the relationships of the connected data sources, so it can update the digital twin with real-time information from the system being modeled. Customers can import existing 3D models, directly into AWS IoT TwinMaker to easily create 3D visualizations of the physical systems and overlay the data from the knowledge graph on to the 3D visualizations to create the digital twin. Once the digital twin has been created, developers can use an AWS IoT TwinMaker plugin for Amazon Managed Grafana to create a web-based application that displays the digital twin on the devices plant operators and maintenance engineers use to monitor and inspect facilities and industrial systems. AWS IoT TwinMaker is available today in preview in U.S. East - N. Virginia, U.S. West - Oregon, Asia Pacific -Singapore, and Europe - Ireland, with availability in additional AWS Regions coming soon. Carrier (CARR), Siemens (SIEGY), and Accenture (ACN) are among customers and partners using AWS IoT TwinMaker.

13:51 EST Amazon Web Services announces AWS IoT FleetWise - Amazon Web Services announced AWS IoT FleetWise, a new service that makes it easier and more cost-effective for automakers to collect, transform, and transfer vehicle data to the cloud in near-real time. "With AWS IoT FleetWise, automakers can easily collect and organize data in any format present in their vehicles (regardless of make, model, or options) and standardize the data format for easy data analysis in the cloud," the company said. "AWS IoT FleetWise helps automakers efficiently transfer data to the cloud in near-real time using the service's intelligent filtering capabilities that allow developers to reduce network traffic by selecting the data to transfer and defining rules for when to transfer it based on parameters like weather conditions, location, or vehicle type. Once the data is in the cloud, automakers can use it for applications that remotely diagnose issues in individual vehicles, analyze vehicle fleet health to help prevent potential recalls or safety issues, or improve advanced technologies like autonomous driving and advanced driver assistance systems with analytics and machine learning. There are no upfront commitments or fees to use AWS IoT FleetWise, and customers only pay for the underlying services used."

13:26 EST Sintx says met with multiple companies at IAOCI to discuss possible partnerships - Sintx Technologies stated in a post to its corporate news website dated November 30: "In August 2021, Michael Marcroft, SINTX VP of Business Development, attended the International Academy of Ceramic Implantology, IAOCI, World Congress to better understand the latest trends and meet with prospective partners, within the ceramic dental implant industry. It was a fantastic three-day event which very much supported the idea that ceramic dental implants are a critical component of future dentistry. SINTX met with multiple exhibiting companies, to explore the potential for partnership in commercializing a silicon nitride dental implant system... Silicon nitride's properties, unique even among other ceramic implant materials, could be a potential game changer. We are excited to explore the possibilities with prospective dental implant partners and look forward to success within this critical medical specialty." Reference Link

12:41 EST AMC Theatres, Sony choose WAX Blockchain for 'Spider-Man' NFT promotion - WAX Blockchain has been chosen by Sony Pictures (SONY) and AMC Theatres (AMC) for Sony Pictures' "Spider-Man: No Way Home" NFT Promotion, the first ever NFT promotion between a studio and a major theatrical exhibitor. "In addition to being eco-friendly, it was essential that the process for receiving the NFT was also consumer friendly," said Adam Aron, Chairman of the Board and CEO, AMC Theatres. "It's easy to use and already widely adopted WAX Cloud Wallet combined with no gas fees for minting, sending and receiving NFTs gave us confidence that everyone, including first time blockchain users, would be able to participate in the promotion."

12:21 EST Fluor announces $2.8B annual contract for Nuclear Production One joint venture - Fluor announced that the Department of Energy's National Nuclear Security Administration selected Nuclear Production One, a Fluor-led joint venture with Amentum, to lead the Y-12 National Security Complex and Pantex Plant Management and Operating contract. The contract includes a four-month transition period and a five-year base period with five, one-year options, for a total contract period of up to 10 years if all options are exercised. The estimated value of the contract is $2.8B annually.

12:00 EST RLX Technology falls -16.5% - RLX Technology is down -16.5%, or -83c to $4.24.

12:00 EST Local Bounti falls -29.3% - Local Bounti is down -29.3%, or -$2.64 to $6.36.

12:00 EST Scor ADR rises 8.1% - Scor ADR is up 8.1%, or $1.25 to $16.68.

11:49 EST Lincoln Financial appoints Jayson Bronchetti CIO, Chris Neczypor CSO - Lincoln Financial Group announced that Jayson Bronchetti has been named Chief Investment Officer, and Chris Neczypor has been named Chief Strategy Officer, both effective today. Bronchetti and Neczypor will both report to Ellen Cooper, who will be appointed President and CEO of Lincoln Financial following the 2022 Annual Meeting of Shareholders in May. Bronchetti succeeds Cooper as CIO and will continue to build on and execute the general and separate account investment strategy, overseeing more than $300B in assets. In the newly created Chief Strategy Officer role, Neczypor will lead Lincoln Financial's long-term enterprise strategic direction and approach to drive business growth to deliver value for shareholders and customers. This will include leading corporate development including mergers and acquisitions, enterprise-wide long-term strategic planning and competitive intelligence. Bronchetti and Neczypor each have more than 20 years of industry experience and will both join the company's Senior Management Committee, which drives the company's strategy, following Cooper's transition to President and CEO in May 2022. Bronchetti most recently served as head of Corporate Fixed Income for Lincoln Financial and is the president and chairman of Lincoln's mutual fund platform.

11:46 EST Nasdaq to begin migrating markets to AWS starting in 2022 - Nasdaq (NDAQ) and Amazon Web Services (AMZN) announced a multi-year partnership to build the next generation of cloud-enabled infrastructure for the world's capital markets. Beginning in 2022, Nasdaq plans to migrate its North American markets to AWS in a phased approach, starting with Nasdaq MRX, a U.S. options market. Nasdaq will use a new edge computing solution that is co-designed by Nasdaq and AWS and specifically developed for market infrastructure. This solution may also be used by other market infrastructure operators and market participants to move their trading systems to the cloud. In addition, the partnership will include opportunities to explore new ways to leverage AWS's cloud capabilities across Nasdaq's anti-financial crime, data and analytics, and market infrastructure software solutions.

11:28 EST Old Second Bancorp, West Surburban announce shareholder approval of merger - Old Second Bancorp and West Suburban Bancorp jointly announced that each has received shareholder approval for the merger of West Suburban into Old Second in a cash and stock transaction. The merger, which was announced on July 25, 2021, is expected to close on December 1, 2021, subject to satisfaction of customary closing conditions. The combined company, on a pro forma basis using September 30, 2021 financial information, will have approximately $6.2 billion in assets, $5.3 billion in deposits and $3.4 billion in loans, and will be one of the largest community banks under $10 billion in assets in the Chicago market.

10:32 EST Comcast, Disney announce content carriage agreement - Comcast (CMCSA) and The Walt Disney Company (DIS) announced the companies have renewed their content carriage agreement and will continue to make Disney's lineup of sports, news, kids, family and general entertainment programming available to Xfinity TV customers. The multi-year agreement encompasses continued distribution of Disney's cable channels, including the ESPN networks, the Disney branded channels, Freeform, the FX networks, and the National Geographic channels. The renewal also includes continued distribution of the SEC Network, now in its eighth season, as well as retransmission consent for the ABC Owned Television Stations in New York, Chicago, Philadelphia, San Francisco, Houston, Raleigh-Durham and Fresno. Additionally, Comcast will distribute the ACC Network to its Xfinity customers, "allowing fans and followers of the Atlantic Coast Conference to access the multiplatform network in the coming weeks," the companies said.

10:21 EST Coinbase to acquire cryptographic security company Unbound Security - In a company blog post, Coinbase announced the acquisition of Unbound Security. The company said, Based in Israel, it is a pioneer in a number of cryptographic security technologies, including the emerging field of secure multi-party computation, a highly advanced technology for which Unbound Security's co-founder, Yehuda Lindell, is a world leader. With this acquisition, Coinbase not only gains access to some of the world's most sophisticated cryptographic security experts, including Unbound Security co-founder and current Vice President of Research and Development, Guy Peer, who brings more than 20 years of experience in cryptographic security, but also a presence in Israel, a well-established and rapidly growing technology hub. This presence in Israel will add an additional powerful prong to Coinbase's global talent acquisition strategy, following on closely to recent thrusts into engineering talent bases such as India, Singapore and Brazil. Crypto can't grow without strong cryptography and strong security, but it also needs to be user friendly. Secure multi-party computation is an application of advanced mathematics to enable crypto assets to be stored, transferred and deployed more securely, easily and flexibly than ever before...In addition to the technological expertise that we will gain through this acquisition, we also plan to establish a tech center of excellence in Israel that will ensure that Coinbase is always at the bleeding edge of security and blockchain technology. We've long recognized Israel as a hot bed of strong technology and cryptography talent, and are excited to continue to grow our team with some of the best and brightest minds in these fields. The Unbound Security team will form the nucleus of this new research facility, which we plan to grow over time. We're always proud to welcome top talent to Coinbase and the Unbound Security team represents the very best expertise in its field. We look forward to working with them over time to move the entire state of cryptographic security forward and to continue delivering the highest levels of security to our customers. Please join us in welcoming the team to Coinbase. This acquisition is subject to customary closing conditions and is expected to close in the coming months." Reference Link

10:07 EST AT&T Communications' CEO sees no downward pressure on ARPU - "Given the amount of international roaming revenue that was once in our ARPU [or Average Revenue Per User] and that hasn't fully recovered yet gives me a higher degree of confidence that after all the scale, all the volume that we have put through the program... we are at scale and I don't anticipate any additionally dilution on ARPU. I actually see upside on ARPU as roaming revenues will certainly at some point be a little more fully recovered to pre-pandemic levels. And that might take an extra quarter or two. But we do expect to recover at some point in the future... I don't see any downward pressure on ARPU; I would call that to be stable in 2022 and going forward," AT&T Communications' CEO Jeff McElfresh said at the Wells Fargo TMT Summit 2021.

10:05 EST Sheffield enters retail financing program agreement with American Honda - sheffield Financial, a division of Truist Bank, Member FDIC, and American Honda Motor Co. recently agreed to renew a multiyear financing services program agreement, effective immediately. Honda Power Equipment, a business unit of American Honda Motor Co. Inc., markets outdoor power products including generators, lawn mowers, pumps, snow blowers, tillers and trimmers. Honda Marine operates under the American Honda Motor Co. Inc. umbrella marketing a wide array of four-stroke, outboard marine engines. The agreement allows Sheffield to provide lending services to Honda Power Equipment and Honda Marine customers through their respective dealer networks. The contract covers installment financing for Honda marine engines, boat packages that include Honda engines, Honda generators, lawn mowers, pumps, snow blowers, tillers and trimmers.

10:00 EST Micro Focus falls -7.2% - Micro Focus is down -7.2%, or -36c to $4.64.

10:00 EST Barnes & Noble Education falls -11.7% - Barnes & Noble Education is down -11.7%, or -$1.04 to $7.84.

10:00 EST AngloGold Ashanti rises 6.3% - AngloGold Ashanti is up 6.3%, or $1.27 to $21.42.

09:59 EST AERC Stock trading resumes

09:56 EST AT&T Communications' CEO expects activity level for postpaid to subside in 2022 - "The stimulus programs have put some extra cash in household budgets. We're not expecting that level of activity to continue into 2022 and beyond. In a three-player market with the integration between Sprint and T-Mobile [TMUS], we suspect the activity level for postpaid in 2022 is probably going to subside. We're not forecasting it to be as strong as it was this year. But we are expecting to take more than our fair share, more than our market share in terms of that growth opportunity in the wireless business over the next 2-3 years... There are pockets of growth for us to continue to pursue," AT&T Communications' (T) CEO Jeff McElfresh said at the Wells Fargo TMT Summit 2021.

09:52 EST Pioneer Power trading resumes

09:47 EST Pioneer Power trading halted, volatility trading pause

09:47 EST RLX Technology falls -10.5% - RLX Technology is down -10.5%, or -53c to $4.54.

09:47 EST Tuya rises 5.3% - Tuya is up 5.3%, or 29c to $5.72.

09:47 EST Gold Fields rises 6.2% - Gold Fields is up 6.2%, or 68c to $11.60.

09:43 EST Olema Pharmaceuticals trading resumes

09:40 EST IsZo says all six nominees elected to Nam Tai Property board - IsZo Capital Management, which beneficially owns approximately 15.2% of the outstanding shares of Nam Tai Property, commented on the preliminary results of the Company's meeting of shareholders held earlier today. Preliminary voting results provided by IsZo's proxy solicitor indicate that shareholders have elected its entire six-member slate to Nam Tai's Board of Directors. In addition to incumbent directors Peter R. Kellogg and Mark Waslen, Nam Tai's reconstituted Board will include Michael Cricenti, Cindy Chen Delano, Bo Hu, Leung Lin Cheong Louis, Paula J. Poskon and Jeffrey Tuder. Brian Sheehy, Founder and Managing Member of IsZo, commented: "After spending the past 18 months fighting entrenchment maneuvers and navigating protracted litigation, we are very pleased that Nam Tai's shareholders finally had their voices heard at today's Special Meeting. Preliminary results indicate that holders of nearly 60% of Nam Tai's outstanding shares, including more than 94% of holders unaffiliated with Kaisa Group Holdings Ltd., voted to remove a majority of the incumbent directors and elect six new highly-qualified and independent individuals to the Company's Board. We firmly believe that reconstituting a majority of the Board with our slate positions Nam Tai to enhance its corporate governance, establish a credible capital allocation policy and take steps to unlock the significant value within its real estate portfolio. We also want to take this opportunity to thank our fellow shareholders for their overwhelming support during what was a challenging and lengthy campaign for sorely-needed boardroom change. Today should mark the beginning of a promising new chapter for Nam Tai and all of its stakeholders, including the local communities the Company operates within across mainland China."

09:34 EST Nortech Systems anounces $6.1M PPP loan forgiveness - Nortech Systems provided an update related to the status of its Paycheck Protection Program, or PPP, loan forgiveness application with the U.S. Small Business Administration, or SBA. As previously announced, on April 21, 2020, the company executed a promissory note to Bank of America National Association, as lender, in the aggregate principal amount of $6.1M under the PPP. The PPP was established under the Coronavirus Aid, Relief, and Economic Security Act and is administered by the SBA. The Company submitted its PPP loan forgiveness application to the SBA through BOA. On November 29, the company received notification through BOA that the PPP loan and accrued interest has been fully forgiven by the SBA and the forgiveness payment date was November 3. The financial impact of PPP loan forgiveness will be reflected in the company's results for Q4 ending December 31, 2021.

09:33 EST Nevada reports October statewide gaming win up 48.54% to $1.22B - Nevada reports October Las Vegas Strip gaming win up 86.88% compared to 2020 to $702.19M. Publicly traded companies in the casino and gambling space include Boyd Gaming (BYD), Caesars (CZR), Churchill Downs (CHDN), DraftKings (DKNG), Flutter Entertainment (PDYPY), Gan Limited (GAN), Las Vegas Sands (LVS), MGM Resorts (MGM), Penn National (PENN), William Hill (WIMHY) and Wynn Resorts (WYNN).

09:24 EST MongoDB to use its Atlas in AWS Marketplace in Q1 of FY22 - MongoDB (MDB) announced plans to use MongoDB Atlas in AWS Marketplace in calendar Q1 2022. With the launch of a pay-as-you-go MongoDB Atlas with Free Trial in AWS Marketplace, developers will have a simplified subscription experience, and enterprises will have another way to procure MongoDB in addition to privately negotiated offers already supported on AWS Marketplace. AWS Marketplace is an Amazon (AMZN) business.

09:20 EST Twitter expands private information policy to include media - Twitter Safety stated in a blog post: "As part of our ongoing efforts to build tools with privacy and security at the core, we're updating our existing private information policy and expanding its scope to include 'private media.' Under our existing policy, publishing other people's private information, such as phone numbers, addresses, and IDs, is already not allowed on Twitter. This includes threatening to expose private information or incentivizing others to do so... While our existing policies and Twitter Rules cover explicit instances of abusive behavior, this update will allow us to take action on media that is shared without any explicit abusive content, provided it's posted without the consent of the person depicted. This is a part of our ongoing work to align our safety policies with human rights standards, and it will be enforced globally starting today." Reference Link

09:16 EST 23andMe appoints Joseph Arron as CSO - 23andMe Holding announced the appointment of Joseph R. Arron, M.D., Ph.D., as the company's new Chief Scientific Officer. In this role, Dr. Arron will determine and prioritize 23andMe's therapeutic programs and indications, including drug discovery and target validation efforts, and build out a pipeline that yields clinical stage programs. Dr. Arron will report to Kenneth Hillan, Head of Therapeutics at 23andMe. In addition to prioritizing 23andMe's drug discovery pipeline, Dr. Arron is charged with leading the company's scientific teams across multiple therapeutic areas, including immuno-oncology, immunology, respiratory, and cardiovascular disease, among others. Dr. Arron will lead 23andMe's therapeutics discovery strategy from early discovery to the IND-enabling studies stage. Dr. Arron previously served as Vice President and Senior Fellow, Immunology Research at Genentech.

09:14 EST Duck Creek Technologies selected by Arbella Insurance Group for SaaS solutions - Duck Creek Technologies announced that Arbella Insurance Group, a North American underwriter of personal and commercial lines insurance products and longtime Duck Creek AgencyPortal customer, has selected Duck Creek Rating, Policy, Billing, Claims, Insights, Producer, and Distribution Management to streamline its personal lines operations. "This commitment represents a major digital transformation move for Arbella and is yet another sign that insurers worldwide are adopting SaaS solutions for the most critical functions of their organizations," said Michael Jackowski, CEO of Duck Creek Technologies. "Duck Creek OnDemand will let Arbella continue to focus on its customers, agents, and products, while we take care of day-to-day IT operations and application upgrades behind the scenes. We are thrilled to expand our relationship with Arbella and look forward to continuing to help them grow."

09:12 EST Clarus Therapeutics announces issuance of two patents for JATENZO - Clarus Therapeutics announced that the United States Patent and Trademark Office has issued two new patents for claims that cover Clarus' oral testosterone replacement product, JATENZO. Patent No. 11,179,403 entitled "Oral Testosterone Ester Formulations and Methods of Treating Testosterone Deficiency Comprising Same" and patent No. 11,179,402 entitled "Pharmaceutical Delivery Systems for Hydrophobic Drugs and Compositions Comprising Same" both cover Clarus' approved product JATENZO. The new patents will expire in 2030 and 2026, respectively.

09:11 EST Comtech awarded 5G deal with Canadian tier-one carrier in Q122 - Comtech Telecommunications announced that during its first quarter of fiscal 2022, it was awarded a contract to provide Gateway Mobile Location Center and Location Management Function solutions which enable new positioning technologies for a Canadian tier-one mobile network operator's 5G network. "5G is the next generation of telecom infrastructure," said Fred Kornberg, Chairman of the Board and Chief Executive Officer of Comtech Telecommunications Corp. "Comtech's 5G innovations will bring more and faster services to this Canadian carrier. We are proud to be at the forefront of this pioneering technology."

09:11 EST Sumo Logic announces four AWS Quick Start integrations - Sumo Logic announced four new Sumo Logic AWS Quick Start integrations for rapid access to security and compliance insights and support for Amazon Inspector. Aligned with the AWS Security Reference Architecture, the Quick Start integrations automate the collection and analysis of security events. With these new integrations and insights, Sumo Logic customers can securely embark on a cloud migration and adoption journey by leveraging an automated, repeatable, intelligence framework to accelerate discovery and response to security threats.

09:10 EST CleanSpark unveils new brand identity, including new logo and website - CleanSpark unveiled a new logo, including a new wordmark and icon, and a new website. The new brand identity reflects the Company's strategic focus on sustainable bitcoin mining using the Company's background in energy technology. "As CleanSpark continues to expand capacity across its portfolio of mining facilities, the unique advantages of having a background in energy technology and management is becoming increasingly valuable: CleanSpark is developing some of the most efficient mining operations in the industry," the company said. "Mining Bitcoin has become an increasingly important business segment for CleanSpark. We leverage our deep energy background to make our operation sustainable, which is important given how energy-intensive this industry is-so we wanted our updated brand to reflect that," said Matthew Schultz, CleanSpark's executive chairman. "I'm very proud of our in-house design team, who did a spectacular job of understanding and then depicting what we stand for."

09:08 EST RealNetworks' SAFR facial recognition technology selected for FACEma system - SAFR from RealNetworks was selected as the facial recognition technology provider for a new biometric access control system in use at Japanese construction sites. Developed by Nextware corporation in conjunction with Kids-Way corporation, the new FACEma access control and health management system enables construction site workers to automatically register their attendance and departure while also checking body temperatures for fever symptoms. Automated access control is being promoted at construction sites to reduce operational costs and human errors while protecting the health and safety of workers. Attendance and departure management in collaboration with health management is a key component of advancing the digital transformation of the Japanese construction industry. At the behest of the Japanese Ministry of Land, the FACEma access control system utilizes the existing CCUS central database which contains worker qualifications, insurance enrollments and onsite working history records.

09:07 EST Pros Holdings digital marketing firm EveryMundo for $80M in cash at closing - Pros Holdings announced the acquisition of EveryMundo, a privately held company based in Miami, Florida. PROS will pay $80M in cash at closing, subject to certain customary adjustments, and deliver approximately $10m in stock in the future, subject to certain conditions. "EveryMundo is a digital offer marketing pioneer that enables brands to broaden their digital reach and deepen customer engagement, pulling them in to direct selling motions to create superior brand experiences and foster loyalty over time," said the press release statement. "We are thrilled to welcome the EveryMundo team to the PROS family," said PROS President and Chief Executive Officer Andres Reiner. "Brands have no choice but to be present everywhere their customer and prospects find themselves but winning in today and tomorrow's market will require brands to earn more direct engagement and deliver the experiences their customers value most. With EveryMundo, our collective portfolio gives brands much greater control over direct and indirect channels they participate in to consistently deliver superior brand experiences that exceed customers' expectations every time, regardless of channel."

09:07 EST Pacific Biosciences appoints Jason Kang as VP, GM for Asia-Pacific region - PacBio welcomes Jason Kang as Vice President and General Manager for the company's Asia-Pacific region. Jason will be responsible for leading and developing PacBio's commercial team in Asia-Pacific as the company continues to expand its reach in the region to support rapidly growing demand for HiFi sequencing. Kang brings more than 25 years of global experience in the genomics industry to PacBio, having led Illumina's Korean commercial operations for six years before launching Helixrus, which specializes in distributing large scale populational genomics and clinical sequencing software solutions in single-cell RNA and rare diseases.

09:04 EST Senmiao Technology launches proprietary online ride-hailing platform - Senmiao Technology announced the launch of its proprietary online ride-hailing platform for drivers in Suzhou, China. With the launch in Suzhou, Senmiao's platform is now available in 12 cities across China, six cities in Sichuan Province and six major cities in other provinces in China. With a population of approximately 12.7M, Suzhou is recognized as one of the important central cities in the Yangtze River Delta by the State Council of China. Located just west of Shanghai, Suzhou is a national high-tech industrial base and a popular tourist destination known for its scenic canals, bridges and classical gardens.

09:02 EST AMD EPYC processor offerings expand at AWS - AMD (AMD) announced Amazon (AMZN) Web Services, AWS, has expanded its AMD EPYC processor-based offerings with the general availability of general-purpose Amazon EC2 M6a instances. The M6a instances are powered by 3rd Gen AMD EPYC processors delivering, according to AWS, up to 35% better price-performance compared to the previous M5a instances and a 10% lower cost than comparable x86-based EC2 instances. "Our 3rd Gen AMD EPYC processors provide Amazon EC2 users excellent scalability and impressive price-performance compared to previous generation Amazon EC2 M5a instances. This announcement shows our strong collaboration as well as highlights our overall momentum in cloud infrastructure," said Lynn Comp, corporate vice president, Cloud Business, AMD. "Our work with AWS exemplifies our commitment to giving end users innovation and performance for their cloud environments and workloads." The Amazon EC2 M6a instances are EC2 instances powered by 3rd Gen AMD EPYC CPUs, which are to be followed by additional instances going forward. Compared to the existing M5a instances, M6a takes advantage of the new 'Zen 3' core for better price-performance, and more core density. The latest AWS M6a instances powered by 3rd Gen AMD EPYC processors are available in AWS US East, US West, Europe, and Asia Pacific Regions.

09:01 EST ViacomCBS to sell CBS Studio Center for $1.85B - ViacomCBS announced it has entered into a definitive agreement to sell CBS Studio Center and its associated operating business to a partnership formed by Hackman Capital Partners, LLC and Square Mile Capital Management, LLC for approximately $1.85B. The transaction is the result of a widely marketed sale process, which attracted interest from a number of buyers, reflecting the value of CBS Studio Center as a best-in-class studio lot in the highly competitive Los Angeles studio marketplace. The property sits on a 55-gross-acre site in Studio City and consists of over 1M square feet of space, including 22 stages, production office and support buildings, third-party tenant offices, a purpose-built broadcast center and filmable backlot locations. At closing, CBS Broadcasting Inc. will enter into a long-term lease-back of the Broadcast Center, which is home to television stations CBS 2 and KCAL 9. ViacomCBS will continue to occupy stages and produce content on the lot, as well as enter into a short-term lease-back of certain portions of the property in order to manage the transition of ViacomCBS employees to other locations. The transaction is expected to close in 2021, subject to customary closing conditions, including regulatory approval.

09:00 EST Deciphera Pharmaceuticals trading resumes

08:54 EST Diana Shipping completes OceanPal spin-off - Diana Shipping announced that it has completed the spin-off of its wholly-owned subsidiary, OceanPal Inc., effective November 29, 2021. The Company's shareholders received one OceanPal Inc. share for every 10 shares of Diana Shipping Inc. held on the record date of November 3, 2021. To the extent the distribution would have resulted in any shareholder owning a fractional share of OceanPal Inc., such fractional share was rounded up to the next whole number of shares.

08:46 EST Omniq closes previously announced notice to acquire additional 26% of Dangot - OMNIQ has closed on its previously announced notice to acquire an additional 26% of Dangot Computers increasing OMNIQ's ownership to 77%, effective from October 1st, 2021. The Company has paid $4,035,000 from its working capital and a straight loan from an Israeli commercial bank. "Based on the five months of working together, management of OMNIQ strongly believes that Dangot's innovative product offerings fit OMNIQ's target markets, and as such will be leveraged by its strong sales team in the US market. At the same time, OMNIQ believes it can accelerate merging its AI products into the supply chain customers served by both companies," the company said.

08:44 EST E-Home Household Service acquires 51% of Fuzhou Sijie Cleaning - E-Home Household Service Holdings announced that its affiliated variable interest entity, Pingtan Comprehensive Experimental Area E Home Service had entered into an equity transfer agreement to acquire 51% equity interests of Fuzhou Sijie Cleaning Service in cash. The acquisition marks a significant step of E-Home expanding its household cleaning business to public places cleaning market and will improve E-Home's cleaning business service capacities and scopes.

08:44 EST Lineage Cell Therapeutics reports 4th case of retinal tissue regeneration - Lineage Cell Therapeutics announced that restoration of retinal tissue was observed in a fourth patient enrolled in the Company's Phase 1/2a clinical study of its lead product candidate, OpRegen. Retinal tissue restoration and improved visual acuity has now been observed in all four better vision patients treated in Cohort 4, where surgeons successfully covered the majority of the area of atrophy with a suspension of OpRegen cells. Outer retinal layer restoration, which was observed using clinical high-resolution Optical Coherence Tomography , was evidenced by the presence of new areas of retinal pigment epithelium monolayer with overlying ellipsoid zone, external limiting membrane, and outer nuclear layer, which were not present at the time of baseline assessment. These new and additive findings continue to support the Company's view that atrophic AMD is not an irreversible, degenerative condition and that some portion of diseased retinal tissue may be recoverable. OpRegen is an allogeneic RPE cell transplant in development for the treatment of age-related macular degeneration with geographic atrophy , or dry, or atrophic, AMD. "After reporting three previous cases of retinal restoration over the course of the last two years, we have been carefully examining the other Cohort 4 patients. We have put significant work into reviewing images from the remaining patient who had the majority of the area of atrophy covered by the OpRegen suspension at the time of surgical implant. I am pleased to report that at the scheduled Month 12 post-operative visit for this patient, although less prominent than the 3 previously reported cases due to a smaller area of atrophy at baseline, there is clear evidence of retinal restoration in some areas, and the total area of atrophy as calculated using square root transformation, or SQRT, is smaller than the size calculated at baseline," stated Jordi Mones, M.D., Ph.D., Director, Institut de la Macula and Director, Principal Investigator and Founder, Barcelona Macula Foundation. "The finding of a fourth case of restoration further supports our goal of showing that atrophic age-related macular degeneration can be responsive to this type of cell therapy. Dry AMD is a progressive disease and halting or reversing an area of atrophy does not occur spontaneously, which we believe makes the durability and reproducibility of these changes unprecedented within the field. With 12 months of follow-up complete, I am eager to have these cases submitted for peer-reviewed publication." "We have treated 24 patients with OpRegen, 12 of which were not legally blind at baseline and represent our intended treatment population. Among these 12 patients, four received thorough coverage of OpRegen cells across the majority of the atrophic area and experienced a cessation or reversal of their areas of atrophy at 12 months and continue to be followed. These patients also experienced increases in their visual acuity in their treated eye. We believe these four patients represent the only examples of an experimental treatment for dry AMD which can reduce an area of atrophy in humans, rather than simply slow its growth," added Brian M. Culley, Lineage CEO. "Restoration of retinal tissue using cell therapy represents a paradigm shift compared to conventional approaches, which to date have only shown an unremarkable slowing of progression. In addition to being well tolerated to date, the durability of changes to areas of atrophy and improvements in visual acuity support the continued and rapid clinical development of OpRegen. Alongside our advisors, we currently are preparing for multiple engagements with FDA to discuss aspects of OpRegen's designation, our manufacturing plans, and the design of a later-stage clinical trial to begin next year. We anticipate the first of these engagements will begin next month and continue in the first quarter of 2022."

08:43 EST Genius Sports CEO Mark Locke purchases 50,000 shares of common stock - Genius Sports announces the purchase of common stock on the open market by individual members of the company's board of directors, as follows. Chairman of the board of directors and independent director, David Levy bought 25,000 shares. CEO and executive director Mark Locke purchased 50,000 shares. Director, Daniel Burns, acting as beneficial owner of Carbon Group purchased 7,480 shares. Independent director, Niccolo de Masi and Harry You bought 100,000 shares.

08:42 EST Assure Holdings closes $5.2M from private placements - Assure Holdings is pleased to announce that the Company completed a non-brokered private placement, with participation by Assure management and certain directors, employees and consultants, of 70,300 common shares of the Company at an issue price of US$6.19 per share, for aggregate gross proceeds of approximately US$435,000. The issue price was determined in the context of the market and in accordance with Nasdaq listing requirements and following the end of the Company's trading blackout period under its insider trading policy. The Offering follows the Company's announcement on November 15, 2021 of the closing of a brokered private placement whereby the Company raised approximately US$4.75 million at an issue price of US$5.25 per share. There were no warrants issued in connection with the Offering and the Prior Offering. No commissions or fees were paid in connection with the Offering. The net proceeds of the Offering and Prior Offering are expected to be used to service the previously announced system-wide contract with Premier, Inc., expand the Company's high-margin remote neurology services platform, extend the Company's operational footprint into new states and continue to build infrastructure that supports the Company's growth initiatives and for general working capital purposes. The Offering remains subject to the final approval of the TSX Venture Exchange. This press release does not constitute an offer to sell or the solicitation of any offer to buy securities nor shall there be any offer, solicitation or sale of the securities in any jurisdiction where such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

08:40 EST AgeX's licensee ImStem announces 1st U.S. MS patient dosed with IMS001 - AgeX Therapeutics announced that ImStem Biotechnology has dosed the first U.S. multiple sclerosis patient with ImStem's lead investigational drug candidate IMS001 at the Shepherd Center in Atlanta, GA. IMS001 was derived by ImStem from AgeX's pluripotent stem cell line designated ESI-053, under a non-exclusive sublicense from AgeX. AgeX will be entitled to receive revenues in the form of royalties on the sale of IMS001 if successfully developed by ImStem and approved for marketing by the FDA or foreign regulatory authorities, as well as a share of certain other revenues that ImStem may receive in connection with the development or commercialization of IMS001, in multiple sclerosis. IMS001 is derived from AgeX pluripotent stem cells induced to differentiate into mesenchymal stem cells, and is an investigational, allogeneic cell product to be administered intravenously to patients suffering from MS. IMS001 is believed to be the first MSC product derived from an ESC line to be accepted for a human trial by the FDA . ImStem plans to continue enrollment in a dose-escalating, open-label study to evaluate the safety, tolerability, and exploratory efficacy of a single dose of intravenous IMS001 in patients with relapsing-remitting, secondary, or primary progressive MS for whom other treatments have failed. "After decades of ground-breaking work with human embryonic stem cells in the biopharma industry, it is fantastic to see cellular therapies derived from them now being explored in clinical trials," said Dr. Nafees Malik, Chief Operating Officer of AgeX. "The ESI stem cell lines are distinguished as the first clinical-grade human pluripotent stem cell lines created under Good Manufacturing Practices, and we wish to expand access to them for the derivation of cell therapies, by working with academic and industry partners, like ImStem. Also, ESI cells are among only a small number of pluripotent stem cell lines from which a derived cell therapy product candidate has gained FDA IND clearance for human studies."

08:38 EST Quotient announces appointment of Esteban Uriarte as CMOO - Quotient announced Esteban Uriarte as the Company's Chief Manufacturing Operations Officer, CMOO. Uriarte will assume the responsibilities of CMOO on February 1st, 2022. Uriarte brings 30 years of experience in manufacturing and production operations management in the medical devices and pharmaceutical industries. He joins the Company from Ferring Pharmaceuticals where he served as Senior Manufacturing Director responsible for the headquarters site based in Switzerland and the LatAm region.

08:36 EST ZW Data Action announces strategic cooperation with Weiyou Information - ZW Data Action Technologies announced that the Company has established a strategic cooperation with Shanghai Weiyou Information Technology pursuant to which the parties will jointly develop a Platform. Through the Platform, certain "Blockchain + Insurance" services are expected to be provided for small and medium-sized enterprises, contributing to the insurance ecosystem with a blockchain technology upgrade. Weiyou Information was founded in 2015, and its insurance brokerage and technology platform, Klover InsurTech, focuses on digital insurance services, providing streamlined, transparent, and affordable insurance products and value-added services by leveraging innovative cloud computing and big data internet technology, and complying with insurance and finance regulations. Currently, Weiyou Information has cooperated with many well-known companies, including People's Insurance Company of China, Ping An Insurance, China Pacific Insurance Company, China Life Insurance Company and more, and its business and service cover multiple cities across Eastern, Southern and Central China. The two parties will jointly develop and establish a cost-efficient insurance platform based on ZW Data's blockchain technology. Through the Platform, Weiyou Information will provide one stop services, ensuring that all the processes and data of the related insurance could be verified and tracked, improving the transparency and credibility for all participating parties. In addition to Klover InsurTech's current auto insurance, ZW Data and Weiyou Information will jointly conduct research and development on other types of insurance products. Meanwhile, the Company will cooperate with a variety of new media's platforms to promote the Platform.

08:34 EST Seaspan accepts delivery of an additional two 12,200 TEU containerships - Seaspan, a wholly owned subsidiary of Atlas, announced that it has accepted delivery of an additional two 12,200 TEU containerships. The containerships will immediately begin 18-year charters with a major liner customer. This marks the second and third of five newbuild containerships in this class, the first having been delivered in October, each of which have been delivered approximately two months ahead of schedule. Since November 2020, Seaspan has announced orders for 70 newbuild containerships, representing the addition of 839,000 TEU, which will add over $11B of gross contracted cash flows and bring the fully delivered fleet to 1,959,200 TEU. The chart below summarizes the current status of this newbuild program:

08:33 EST Safe-T reports Q3 EPS (13c), one estimate (9c) - Reports Q3 revenue $3.377M, one estimate $2.99M. Shachar Daniel, Chief Executive Officer of Safe-T, said, "We believe that the impressive financial results achieved in the third quarter of 2021 and through the first nine months of the year, reflect the successful execution of our aggressive growth strategy focused on bringing world-class cybersecurity and privacy technology to consumers and enterprises around the world. We are especially pleased by the performance of our consumer and enterprise privacy businesses which have significantly contributed to our growth as it gains sales traction in large geographic markets including the United States and Western Europe."

08:32 EST Biostage names David Green as CEO - Biostage announced it has hired David Green as its CEO and appointed Green as Chairman of the Board of Directors. Green is the founder and CEO of Zero CarbonTM LLC, an energy-efficiency business. He is also the former CEO and Chairman of Biostage. Green resigned from his roles in Biostage in 2015 after he had been involved in a major road accident

08:28 EST ImmunoPrecise Antibodies updates SARS-CoV-2 PolyTope multi-antibody program - ImmunoPrecise Antibodies is providing an update on its Polytope Development Program. The Company continues to rapidly progress it SARS-CoV-2 multi-antibody cocktail therapy, Polytope, and has met the following milestones: U.S. Food and Drug Administration assessed IPA's pre-investigational new drug application; preclinical safety studies have now commenced as previously scheduled. IPA drafted a pre-investigational new drug PIND application and received feedback from the U.S. Food and Drug Administration . IND-enabling studies have now commenced on schedule with initial IND-enabling data from the studies still expected by the end of 2021. The feedback from the FDA on the PIND file is crucial in preparation for the potential submission to the FDA of a full IND-application, which must be approved by the FDA prior to commencing first-in-human clinical studies. SARS-CoV-2 PolyTope antibody cocktail retains binding efficacy against viral variants-of-concern tested in pre-clinical studies As stated in prior announcements by IPA, the PolyTope strategy is to sustainably combat SARS-CoV-2 and emerging variants, which have the potential to escape protective antibodies via mutations in their antibody-targeted spike protein. IPA's therapeutic multi-antibody cocktail continues to demonstrate binding to spike proteins of all novel viral variants tested by IPA to date. Recent studies confirm that the PolyTope antibody mixture is also resilient to WHO-designated variants-of-concern Lambda and Mu. The Company continues to track efficacy of its proprietary antibodies against a number of novel amino acid mutations from emerging variants-of-concern designated by WHO. As with previous variants, IPA has already begun analysing the recent Omicron variant o assess retention of binding to cell associated Omicron spike protein variant. Protein homogeneity in PolyTope antibody cocktail for production purposes has improved. "Our Polytope program continues to exceed internal expectations and we are cautiously optimistic that it will continue to prove effective against all emerging variants, in particular as our Polytope was conceived with this specific purpose

08:27 EST Duke Energy files agreement with NCUC for solar adopter compensation - Duke Energy has filed an agreement with the North Carolina Utilities Commission, or NCUC, that will align solar adopter compensation to utility system benefits and create long-term stability for the residential solar industry in North Carolina. The net metering agreement was crafted by Duke Energy and the N.C. Sustainable Energy Association; the Southern Environmental Law Center on behalf of Vote Solar and the Southern Alliance for Clean Energy; Sunrun Inc. and the Solar Energy Industries Association. It must be approved by the NCUC. The agreement follows a similar net metering agreement in South Carolina from September 2020. The filing allows for new net metering tariffs to go into effect for customers submitting applications on or after Jan. 1, 2023; will create innovative pricing and incentives for residential solar customers; features rate design mechanisms to properly collect costs of the grid infrastructure needed to serve solar customers; will include cutting-edge retail rates that vary based on the time of day and when the utility is experiencing peak demand.

08:25 EST Deciphera Pharmaceuticals trading halted, news pending

08:23 EST Akoya Biosciences secures CLIA Lab certification - Akoya Biosciences announced that its Advanced Biopharma Solutions laboratory, located in Marlborough, Massachusetts, has received its Certificate of Registration from the Clinical Laboratory Improvement Amendments program, following the receipt of a Massachusetts Department of Public Health clinical laboratory license. This certification enables Akoya's ABS lab to support later stage clinical trial studies with its biopharmaceutical partners. CLIA certification affirms that Akoya's ABS lab processes and services operate under high quality standards and provides a framework for assay development and validation that consistently meets guidelines for accuracy, precision, specificity, sensitivity, and reproducibility. This milestone is an important step towards advancing the company's platforms toward clinical use. It further positions Akoya Biosciences as an attractive partner for biopharmaceutical companies seeking to incorporate its ground-breaking spatial biology technologies into their clinical research, most notably in the expanding field of cancer immunotherapy. The certification will enable Akoya to expand its collaborations with key partners like AstraZeneca and other biopharmaceutical companies working with Akoya's ABS Program. The goal of this program is to enable biopharma partners to leverage Akoya's deep spatial biology expertise and technological innovations from the early stages of clinical trials, potentially, through full companion diagnostic approval. The CLIA certification is the latest milestone in Akoya's ongoing efforts to ensure consistency and standardization of its laboratory processes and results. Important prior milestones include a recent publication in the Journal of Immunotherapy for Cancer on the MITRE Study, demonstrating for the first time a spatial biology workflow with the throughput, accuracy and reproducibility required to serve the translational and clinical markets.

08:21 EST DavidsTea launches C.A.M.P. by DAVIDsTEA x Ethical Tea Partnership project - DAVIDsTEA is pleased to celebrate Giving Tuesday by announcing its commitment to a more sustainable and ethical tea industry, with the launch of its new summer C.A.M.P by DAVIDsTEA x Ethical Tea Partnership project. This project will support the tea-growing community in Zhejiang, China, one of the regions where it sources premium black and green tea bases for some of its top blends.

08:21 EST FactSet announces it has joined the AWS Data Exchange - FactSet (FDS) announced that it has joined Amazon (AMZN) Web Services, AWS, Data Exchange with a comprehensive financial data and analytics offering. FactSet will deploy over 30 proprietary datasets available within the FactSet ecosystem on AWS Data Exchange, which will allow clients to leverage FactSet's leading content for faster, more efficient decision-making. FactSet will also begin listing APIs that allow users to benefit from its portfolio analytics engine without having to be an existing FactSet client. Furthermore, it plans to bring additional APIs to AWS Data Exchange. "FactSet is delighted to offer its data and solutions on AWS Data Exchange," said Jonathan Reeve, Executive Vice President and Global Head of Content and Technology Solutions, FactSet. "Our clients are accelerating their shifts to the cloud to reduce costs, consolidate infrastructure, and eliminate the waste of duplicated data, and AWS is a leader in this space. FactSet's expansion of our data management services to support Amazon Redshift will make our content available to more clients in a streamlined way, improving workflow efficiency."

08:19 EST GBS Inc. announces plans for clinical SARS-CoV-2 antibody trials - GBS announced it will commence preparation for clinical trials of its rapid SARS-CoV-2 Antibody test following the recent successful completion of a clinical validation study. As previously referenced, a clinical validation study was conducted at the Wyss Institute for Biologically Inspired Engineering at Harvard University. The objective of this study was to develop a diagnostic test to detect SARS-CoV-2 IgG in human plasma. The statistical design of the study was powered in accordance with this study objective. Preliminary findings were: The SARS-CoV-2 Antibody biosensor assay was 100% sensitive and 100% specific using positive and negative SARS CoV-2 human plasma samples. The time in obtaining results was less than 10 minutes. Following the above findings, the company is planning to commence clinical saliva SARS-CoV-2 Antibody trials, with the objective of submitting an Emergency Use Authorization request to the United States Food and Drug Administration.

08:16 EST SPX Flow's UHT technology selected by Middle East's dairy producers - SPX FLOW will provide its Ultra High Temperature, or UHT, technology process lines to one of the Middle East's leading dairy producers. The sale comes just days after SPX FLOW and SIG announced something that's unprecedented in the Middle East: a new Technology Center in Dubai that will stretch the value chain all the way from research and development to processing and packaging. The Technology Center will accelerate how customers test a complete delivery solution, speeding up their time to market.

08:16 EST Walgreens Boots Alliance acquires remaining stake of GEHE from McKesson - Walgreens Boots Alliance (WBA) and McKesson (MCK) have reached an agreement for WBA to acquire the remaining 30% share of their GEHE Pharma Handel, or GEHE, and Alliance Healthcare Deutschland, or AHD, joint venture. Following this transaction, WBA will become the 100% owner of the combined GEHE and Alliance Healthcare businesses in Germany. GEHE and AHD successfully combined their operations in the German pharmaceutical market on November 1, 2020. In that transaction WBA became the 70% owner of the joint venture with McKesson holding the remaining 30%. The announcement follows McKesson's announcement in July of the sale of certain European businesses and its intention to exit the European region fully. The transaction is subject to standard regulatory clearance by the relevant local authorities. Financial terms of the transaction have not been disclosed.

08:14 EST Kymera Therapeutics announces FDA clearance of IND for KT-413 - Kymera Therapeutics announced the clearance of its Investigational New Drug application from the U.S. Food and Drug Administration for its IRAKIMiD degrader, KT-413.

08:13 EST Novo Integrated Sciences acquires 91% of Terragenx - Novo Integrated Sciences announced it has acquired 91% of Terragenx and the intellectual property portfolio for the formulation and manufacturing capability to produce a water-soluble iodine micro-nutrient that is FDA and Health Canada approved for over-the-counter and e-commerce distribution. Iodine is a naturally occurring element and essential nutrient used by the thyroid gland to manufacture necessary hormones in the human body. While iodine alone cannot be ingested, Novo has acquired the intellectual property for iodine in an aqueous form that can be safely ingested and has been proven to kill viruses, bacteria and protozoa when sprayed onto your mucous membranes, the entry points for various airborne viruses. The human immune system uses iodine to deactivate viruses in the bloodstream, which may facilitate the production of antibodies for various indications.

08:13 EST GCM Grosvenor makes majority investment in ReSource Waste Services - GCM Grosvenor announces that it has entered into an agreement with ReEnergy Holdings, under which GCM Grosvenor acquired a majority ownership stake in ReSource Waste Services, New England's largest processor of construction and demolition material. GCM Grosvenor's investment will support ReSource's continued growth strategy throughout the greater Boston area and New England. Terms of the agreement were not disclosed. ReEnergy will retain a minority stake in ReSource. ReSource, a wholly owned subsidiary of ReEnergy, is a C&D waste processing and recycling service provider with an integrated network of five facilities located in Massachusetts, New Hampshire, and Maine, which have a combined processing capacity of 1.3 million tons per year. The Company processes waste material into valuable end-products for sale or beneficial reuse. It maintains a leading market presence in the Boston metropolitan area, an area that is expected to continue to drive C&D waste generation in the New England region. GCM Grosvenor's investment, as well as its expertise as a leading infrastructure investor, can help propel ReSource and its team into a new stage of growth, allowing it to continue to expand its network and provide world-class services to an even greater number of customers throughout the region.

08:11 EST Albany International and Safran extend strategic alliance on advanced composites - Safran Aircraft Engines and Albany International announced an agreement extending their partnership to the year 2046. Through this new agreement, the two companies declare their intent to work together on the next generation engines and thus contribute to the 2050 net-zero CO2 emissions commitment of the aviation industry. Bill Higgins, Albany International President and CEO and Jean-Paul Alary, CEO of Safran Aircraft Engines, signed the partnership extension in Villaroche, near Paris. Copyright: R. Alary/Safran. Albany International and Safran signed the original framework agreement in 2006 resulting in the creation of their joint venture for the development of high technology composite parts designed for aircraft engines, landing gears and nacelles. The 3D-woven composite technology designed and developed by Safran in partnership with Albany Engineered Composites, is a major innovation that plays a key role in improving the performance of the new generation LEAP engine of CFM International1, which powers the Airbus A320neo, Boeing 737 MAX and Comac C919 aircraft families. This advanced material is used to manufacture the fan blades, fan case and spacers of the LEAP engine, leading to significant weight savings and contributing to reduced fuel consumption and CO2 emissions of 15 percent. Safran and Albany have also teamed-up to work on the development and production of the GE9X 3D composite fan case for the Boeing 777X. In order to address unprecedented LEAP production ramp-up, the partners have built three state-of-the-art production plants in Rochester in Commercy and in Queretaro . These three sites are dedicated to 3D composite parts and delivered to date more than 130 000 parts of the LEAP engine. "We are pleased to extend our partnership with Safran, building on the success of Albany's proprietary 3D weaving technology and our joint efforts on critical components of the LEAP and GE9X engine programs," said Bill Higgins, Albany International President and CEO. "The goals set for the next-generation of aircraft engines are multi-faceted and technically demanding. Our AEC team is looking forward to further collaboration with our Safran partners to apply our advanced composite technologies to the next generation of aircraft engines that meaningfully raise the bar for fuel-efficiency and contribute to a more sustainable future."

08:11 EST Viridian Therapeutics announces inducement grants under Nasdaq listing rule - Viridian Therapeutics announced that a majority of the independent directors serving on the Company's Board of Directors approved the grant of stock options to purchase an aggregate of 180,000 shares of the Company's common stock to two new employees on the date that each employee commences service with the Company. The Inducement Grants have been granted outside of the Company's Amended and Restated 2016 Equity Incentive Plan but remain subject to the terms and conditions of such Plan. The Inducement Grants were granted as an inducement material to these individuals entering into employment with Viridian in accordance with Nasdaq Listing Rule 5635(c)(4). The Inducement Grants have an exercise price per share that is equal to the closing price of Viridian's common stock on the new employee's Grant Date. The Inducement Grants will vest over a four-year period, with 25% of the shares vesting on the one-year anniversary of the date of grant, and thereafter the remainder of the shares vest in 36 equal monthly installments, subject to continued employment through the applicable vesting dates.

08:10 EST Evofem reports successful Type C meeting with the FDA for EVO100 - Evofem Biosciences reported a successful Type C meeting with the FDA in which agreement was reached on the preliminary submission strategy for EVO100 for two investigational indications: the prevention of urogenital chlamydia in women and the prevention of urogenital gonorrhea in women. There are currently no FDA-approved prescription products to prevent either of these sexually transmitted infections, or STIs. Chlamydia and gonorrhea are the two most frequently reported bacterial STIs in the United States. Evofem's pivotal Phase 3 clinical trial of EVO100 for prevention of chlamydia and gonorrhea in women, EVOGUARD, is currently enrolling 1,730 women at study sites across the US. The Company expects to report top-line EVOGUARD data in the second half of 2022. Positive outcomes could support submission to the FDA for these potential indications in the first quarter of 2023, with an anticipated PDUFA date in the second

08:09 EST WPP acquires Cloud Commerce Group - WPP announced that it has acquired Cloud Commerce Group, or CCG, a UK-based technology company that helps brands to market, sell and deliver their products across ecommerce platforms and marketplaces globally. The platform powers over GBP 1B in gross merchandise value annually through its various integrations. CCG employs over 100 people across Europe. The company will join the Wunderman Thompson global network as part of its commerce and technology proposition.

08:09 EST Kratos Defense receive initial $4M in single award funding on new C5ISR program - Kratos Defense & Security Solutions announced that it has received the initial, approximate $4M in funding on a new, single award, Command, Control, Communication, Computing, Combat System, Intelligence, Surveillance & Reconnaissance, C5ISR, program, with a total potential program value of approximately $75M, including production. Work under this new program award will be performed at secure Kratos production and manufacturing facilities. Due to customer, competitive, security related and other considerations, no additional information will be provided related to this program. Eric DeMarco, President and CEO of Kratos, said, "Kratos is making the internally funded investments required to address our national security customers' most important and time sensitive requirements, with rapid development and fielding of systems that are technologically advanced and relevant to today's environment. We believe that this new, sole source award is representative of Kratos' - listen to the customer, make the investment and provide the solution - organic growth approach."

08:08 EST Jazz enrolls first patient in Phase 3 clinical trial evaluating Zepzelca - Jazz Pharmaceuticals announced that the first patient was enrolled in a Phase 3 clinical trial evaluating Zepzelca, or lurbinectedin, in combination with the PD-L1 inhibitor Tecentriq, or atezolizumab, as a first-line maintenance treatment for patients with extensive-stage small cell lung cancer, or ES-SCLC. The trial, IMforte, conducted in collaboration with F. Hoffmann-La Roche Ltd, will measure the progression-free survival and overall survival benefits of Zepzelca and Tecentriq administered in combination compared to Tecentriq alone.

08:07 EST Microchip announces maXTouch touchscreen controller - As the automotive market continues to demand larger touchscreens with more flexibility in size and shape, Microchip Technology is announcing a new maXTouch touchscreen controller, that allows automotive designers to satisfy various and unique aspect ratios for touch displays in cars. This new offering includes additional functional safety support requested by OEMs. The MXT1296M1T can reconfigure its driving and receiving touch channels to match the exact screen format, from 1:1 to 5:1 aspect ratio, including the popular 8:3 automotive aspect ratio. This feature enables the customer to efficiently use the number of touch channels available, without the need to select a larger, more expensive touch controller. Furthermore, customers can save additional development and validation time and resources by reusing a common PCB design to support different touch sensor aspect ratios. The MXT1296M1T is an industry first to enable the sensor channel reconfiguration by parameters. These settings do not require firmware modification, leading to lower design risk and faster time to market.

08:06 EST Palisade Bio announces EPO granted patent for LB1148 - Palisade Bio announced that the company will be granted a patent from the European Patent Office, EPO, covering its lead investigational drug product, LB1148. The patent will publish on December 22, 2021, and provide protection until 2035. "With the European patent grant, this greatly strengthens the IP protection of our lead drug candidate LB1148 for the global pharmaceutical market. This grant builds upon the corresponding patents in the United States, China, Australia, Japan, India, Mexico, and Taiwan," said Thomas Hallam, Ph.D., CEO of Palisade Bio. "We are continuing to strengthen patent protections for LB1148 and its uses across the globe as we advance our clinical studies with LB1148."

08:06 EST Lightning eMotors appoints Marci Fouts as Chief People Officer - Lightning eMotors announced that Marci Fouts, CCP, SPHR, has joined the company as Chief People Officer, CPO. On January 14 the FCC granted a waiver of certain legacy rules in the 450 MHz Air-Ground Radio band. The FCC provided relief of the rule requiring a minimum transmit power of four watts for the aviation radio. By allowing lower transmit power, the frequency band becomes viable for more highly scaled Unmanned Aerial Systems and Drones. The lower allowable transmit power reduces the size of the power amplifier, one of the main drivers of size and weight of aviation radios. A lighter radio allows for longer flight times before refueling or recharging, while lower transmit power allows for greater frequency reuse. "We are very proud to have delivered our first radio for the licensed Air-Ground Frequency Band based on the FCC's waiver," stated Eric Brock, CEO of Ondas Networks. "The Mercury Radio is another example of innovation being driven by Ondas Networks to enable highly scaled unmanned aerial systems. Our field-tested command and control capabilities, along with our support for multiple licensed frequencies, will provide operators throughout the drone ecosystem with a new option in the 450 MHz band and other bands supporting air to ground communication," concluded Mr. Brock.

08:05 EST Barnes & Noble Education expects to generate positive adjusted EBITDA in FY22 - The company said, "While it is difficult to predict the ongoing effects of the COVID virus, based on its current views, the Company expects to generate positive non-GAAP Adjusted EBITDA in fiscal year 2022, as most schools return to a traditional on-campus environment for learning, events and sporting activities. The Company expects non-GAAP adjusted EBITDA to approach annual pre-COVID levels in fiscal year 2023, based on an expectation that campuses will be able to resume on campus learning, events and sporting activities with substantially less-restrictive COVID-related policies and operating protocols next year, and that there are fewer negative impacts from the broader supply chain issues."

08:04 EST Chinook Therapeutics announces formation of SanReno Therapeutics - Chinook Therapeutics announced the formation of SanReno Therapeutics, a joint venture with an investor syndicate led by Frazier Healthcare Partners and Pivotal bioVenture Partners China, to develop, manufacture and commercialize kidney disease therapies in the People's Republic of China, Hong Kong, Macau, Taiwan and Singapore. Under the terms of the joint venture, Chinook has granted SanReno exclusive rights to develop and commercialize atrasentan and BION-1301 in the Territory in exchange for 50% ownership of SanReno. An investor syndicate led by Frazier Healthcare Partners and Pivotal bioVenture Partners China, along with existing Chinook investors Versant Ventures and Samsara BioCapital, has invested $40M in exchange for the remaining 50% ownership of SanReno. In addition to its equity stake, Chinook is entitled to receive progress-dependent milestone payments and royalties with respect to atrasentan and BION-1301. SanReno will be responsible for all development, manufacturing and commercialization costs for atrasentan and BION-1301 in the Territory, while Chinook will supply clinical trial material and technical support until manufacturing technology transfer has been completed. Chinook retains full rights to atrasentan and BION-1301 outside of the Territory.

08:02 EST AcuityAds appoints Elliot Muchnik as CFO - AcuityAds Holdings announced the appointment of Elliot Muchnik as CFO. Muchnik joins AcuityAds from Richardson Wealth Limited, one of Canada's largest, regulated independent wealth management firms with over $35B in assets under administration, where he served as CFO and Corporate Secretary since 2007. During his tenure with Richardson Wealth, Muchnik helped lead the company to exponential revenue growth. Previously, he was a Senior Vice President and Managing Director at BMO Nesbitt Burns. Muchnik holds a Bachelor of Business Administration from York University. Muchnik will succeed Tatiana Kresling, who has served as the Company's Interim CFO since September 2021.

07:56 EST Capital Bank expands OpenSky card offering to consumers - OpenSky, the digital banking division of Capital Bank, is pleased to announce the expansion of its product offering with the addition of the OpenSky Visa Gold Card. The OpenSky Gold Card is an unsecured credit card that complements the highly rated OpenSky Secured Visa Credit Card. This new addition offers an uninterrupted experience for OpenSky customers who can now more easily continue in their journey from secured to partially secured to unsecured credit card.

07:51 EST MEI Pharma announces 70.3% ORR in TIDAL study evaluating zandelisib - MEI Pharma and Kyowa Kirin announced that the pivotal Phase 2 TIDAL study evaluating zandelisib as a single agent for follicular lymphoma, or FL, patients who received at least two prior systemic therapies demonstrated a 70.3% objective response rate, or ORR, as determined by Independent Review Committee, or IRC, assessment in the primary efficacy population. In addition, 35.2% of patients achieved a complete response. The data are currently insufficiently mature to accurately estimate duration of response, or DOR. In line with previously reported data from the Phase 1B study, zandelisib was generally well tolerated. With 9.4 months median duration of follow-up in the total study population, interim data demonstrated a discontinuation rate due to any drug related adverse event of 9.9%. Patients enrolled in the study will continue to be followed for safety and DOR. Zandelisib is an investigational selective phosphatidylinositol 3-kinase delta inhibitor in clinical development for the treatment of B-cell malignancies. The ongoing TIDAL study is a global, open-label Phase 2 trial evaluating zandelisib as a single agent across two disease cohorts: the first cohort for the treatment of adults with r/r FL and the second cohort for r/r marginal zone lymphoma, in both cases after failure of at least two prior systemic therapies, including chemotherapy and an anti-CD20 antibody. Enrollment in the FL cohort is complete; enrollment in the MZL cohort is ongoing. Subject to the results and discussion with the FDA, TIDAL study data from each study cohort are intended to be submitted to the FDA to support accelerated approval marketing applications. The r/r FL cohort enrolled a total of 121 patients, 91 of which were enrolled in the primary efficacy population for the evaluation of ORR and DOR. The median age of patients with FL was 64 years old. Patients enrolled in both the FL primary efficacy and total patient populations received a median of three prior lines of treatment. Patients were administered zandelisib once daily for two 28-day cycles as response induction therapy, followed thereafter by once daily dosing for the first seven days of each subsequent 28-day cycle, a schedule called Intermittent Dosing Therapy, or IDT. The ORR in the 91 patients with r/r FL enrolled in the primary efficacy population was 70.3%, 95% CI of 59.8, 79.5, as assessed by IRC after a minimum follow-up of six months; the complete response rate was 35.2%, 95% CI of 25.4, 45.9. The ORR represents the primary endpoint of the TIDAL study. As of the data cutoff date, the data are not sufficiently mature to accurately estimate the final DOR in the FL primary efficacy population, a secondary outcome measure of the TIDAL study. However, with a median follow-up time for response of 8.4 months, the median DOR had not been reached. The data cutoff date is approximately six months after the last patient in the primary efficacy population received their first dose of zandelisib. Zandelisib appeared generally well-tolerated in the total TIDAL study population through the data cutoff date. The safety observed in TIDAL was consistent with data previously reported from the Phase 1B study evaluating zandelisib in patients with B-cell malignancies as a single agent or in combination with rituximab. As of the data cutoff date, with a median follow up of 9.4 months in the total FL study population, the incidence of Grade 3 Adverse Events of Special Interest were: 1.7% ALT/AST elevation, 1.7% colitis, 5% diarrhea, 2.5% mucositis, 0.8% pneumonitis, and 3.3% rash. The discontinuation rate due to any drug related adverse event in the group was 9.9%, also as of the data cutoff date. A more complete report of the TIDAL data as of the data cutoff date will be submitted for presentation at upcoming scientific congresses in 2022.

07:42 EST Document Security announces launch of DSS AmericaFirst Quantitative Funds - DSS announced the launch of DSS AmericaFirst Quantitative Funds. DSS AmericaFirst Quantitative Funds is a suite of mutual funds managed by DSS Wealth Management that expects to expand into numerous investment platforms including additional mutual funds, exchange-traded funds, unit investment trusts, and closed-end funds. DSS AmericaFirst Quantitative Funds currently consists of four mutual funds: The DSS AmericaFirst Income Trends Fund, DSS AmericaFirst Defensive Growth Fund, DSS AmericaFirst Risk-On Risk-Off Fund, and DSS AmericaFirst Large Cap Buyback Fund. "Our funds are deploying groundbreaking technologies to provide investors access to innovative quantitative investment opportunities," stated Frank Heuszel, CEO of DSS. "We see substantial growth opportunities in each of these platforms as we capitalize on building and expanding upon an established distribution infrastructure."

07:40 EST Regeneron says antibody-conveyed immunity may be reduced against omicron - Regeneron said it is evaluating REGEN-COV against the omicron variant, "as we routinely do with new World Health Organization-designated variants of concern." The company stated: "The current U.S. Food and Drug Administration Fact Sheet and multiple separate analyses, including a publication in Cell, affirm that REGEN-COV retains potency against the main variants of concern currently circulating within the U.S., including Delta, which remains the predominate strain in the U.S. today. It is important that high-risk patients who are diagnosed with COVID-19 are aware of current authorized treatment options and seek out these therapies early in the course of their infection. To date, there have been no direct data testing the Omicron variant's resistance to vaccine-induced and monoclonal antibody-conveyed immunity. Prior in vitro analyses and structural modeling regarding the individual mutations present in the Omicron variant indicate that there may be reduced neutralization activity of both vaccine-induced and monoclonal antibody-conveyed immunity, including the current REGEN-COV antibodies. Further analyses are ongoing to confirm and quantify this potential impact using the actual Omicron variant sequence. Regeneron has one of the largest collections of fully human monoclonal antibodies targeting SARS-CoV-2, including its current REGEN-COV cocktail and multiple additional antibodies. The first of these additional investigational candidates has already entered into clinical trials, with others nearing clinic readiness. Preliminary analyses suggest that several of these next generation antibodies may have the potential to retain activity against the Omicron variant, as well as the other existing variants of concern. Further in vitro data is expected over the next month." Reference Link

07:38 EST Parsons comments on the signing of the Bipartisan Infrastructure Deal - Parsons Corporation announced it "applauds the signing of the Bipartisan Infrastructure Deal, citing its importance to the future of infrastructure and economic growth in the United States." "The passage of the bipartisan Infrastructure Bill represents an important investment in our nation's future," said Carey Smith, president and chief executive officer of Parsons. "With investments in transportation, power, broadband, and water infrastructure, along with safety, resiliency and cyber initiatives, the new national infrastructure strategy will not only address immediate emergency needs but help improve our national economy. As an industry, we have advanced in digital technologies and smart infrastructure, so this bill is our chance as a nation to not only Build Back Better but Build Back Smarter. We look forward to unleashing Parsons' more than 77 years of broad expertise across the full infrastructure domain and our resilient infrastructure capabilities to help rebuild and secure our nation."

07:37 EST TG Therapeutics says FDA plans to host ODAC meeting on U2 BLA/sNDA - TG Therapeutics announced the U.S. Food and Drug Administration has notified the Company that it plans to host a meeting of the Oncologic Drugs Advisory Committee in connection with its review of the pending Biologics License Application/supplemental New Drug Application for the combination of ublituximab and UKONIQ for the treatment of adult patients with chronic lymphocytic leukemia and small lymphocytic lymphoma. In general, the ODAC reviews and evaluates data concerning the safety and effectiveness of marketed and investigational human drug products for use in the treatment of cancer and makes appropriate recommendations to the Commissioner of Food and Drugs. Although the FDA will consider the recommendation of the ODAC Committee, the final decision regarding the approval of a product is made solely by the FDA. The FDA has notified the Company that potential questions and discussion topics for the ODAC include: the benefit-risk of the U2 combination in the treatment of CLL or SLL, and the benefit-risk of UKONIQ in relapsed/refractory marginal zone lymphoma or follicular lymphoma. In addition, as part of the benefit-risk analysis, the overall safety profile of the U2 regimen, including adverse events, discontinuations due to adverse events, and dose modifications, is expected to be reviewed. The FDA's concern giving rise to the ODAC meeting appears to stem from an early analysis of overall survival from the UNITY-CLL trial. Overall survival was designated as a secondary efficacy outcome in the UNITY-CLL protocol but was not part of the primary analysis in accordance with the study's statistical analysis plan agreed upon via a Special Protocol Assessment, and therefore, was not analyzed or included in the BLA/sNDA. Additionally, the study was not powered for overall survival. As part of the ongoing review of the BLA/sNDA, the FDA requested an early analysis of overall survival from the UNITY-CLL trial. As of September 2021, the cut-off date for the overall survival analysis requested by the FDA during their review, there was an imbalance in favor of the control arm (HR: 1.23) though this result was not statistically significant. However, when excluding deaths related to COVID-19, the two arms were approximately balanced (HR: 1.04) with again no statistically significant difference between the treatment groups with regard to overall survival. The overall survival results are preliminary and the Company will continue to evaluate this endpoint over time as more events are available and will continue to analyze how COVID-19 may be impacting the analysis. The date of the ODAC meeting has not yet been determined, although the FDA has stated that it is targeting holding the ODAC in March or April 2022. Given this timing, we believe it is unlikely that the FDA will make a decision on the BLA/sNDA by the PDUFA goal date of March 25, 2022.

07:36 EST Avicanna enters into intellectual property licensing, distribution agreement - Avicanna announces that it has entered into a partnership with an established Argentine pharmaceutical company to register and commercialize Avicanna's proprietary cannabinoid-based pharmaceutical preparations through the licensing of its intellectual property and supply of its active pharmaceutical ingredients, API. Through the partnership Avicanna will provide a non-exclusive license of the Company's intellectual property related to its proprietary 10% cannabidiol, CBD, pharmaceutical drug preparation. Additionally, the partner will source its pharmaceutical-grade CBD exclusively from Avicanna to manufacture the product for the registration and marketing authorization with the Argentine regulatory agency ANMAT. The marketing authorization of the pharmaceutical preparation is expected to be approved during the second half of 2022 and is expected to be supported with claims related to treatment of epilepsy. "We look forward to entering the Argentine market through a pharmaceutical pathway and to be doing so by delivering our proprietary formulations as solution to patients with unmet medical needs. We are rapidly expanding into the region with innovative and accessible cannabinoid-based pharmaceutical products and are doing so through partnership with reputable industry leaders," stated Lucas Nosiglia, President of Avicanna LATAM.

07:34 EST NextEra Energy to sell 50% stake in renewables project to third party - NextEra Energy (NEE) announced that a subsidiary of NextEra Energy Resources, LLC has entered into an agreement to sell a 50% non-controlling interest in an approximately 2,520 megawatt portfolio of long-term contracted renewables assets to the Ontario Teachers' Pension Plan Board. The remaining 50% interest in the portfolio is under an agreement to be sold by NextEra Energy Resources to NextEra Energy Partners, LP (NEP) pursuant to a purchase and sale agreement executed on Oct. 21, 2021 between a subsidiary of NEP and a subsidiary of NextEra Energy Resources. The sale proceeds are expected to be redeployed into new wind, solar and battery storage growth opportunities, including NextEra Energy Resources' more than 18,000-MW renewables and storage backlog. This attractive capital recycling opportunity provides significant value to NextEra Energy Resources and highlights the value of its renewables development platform. Over the operating life of the assets in the portfolio, NextEra Energy Resources is also expected to receive ongoing annual fee income of approximately $16M in year one and escalating thereafter for operations, maintenance and management services, and the transaction is expected to be accretive to earnings and generate an overall improvement in net present value for NextEra Energy shareholders. NextEra Energy expects to sell the interests in the assets for a total consideration of approximately $849M, subject to working capital and other adjustments, plus the investor's share of the portfolio's total tax equity financings, which is estimated to be approximately $866M at the time of closing. NextEra Energy expects to close the transaction later this year or in early 2022, subject to customary closing conditions and receipt of certain regulatory approvals.

07:34 EST Heat Biologics unveils RapidVax, a novel cellular vaccine platform - Heat Biologics unveiled its new RapidVax cellular vaccine platform at the 2021 World Antiviral Congress. RapidVax is designed as a rapid programmable vaccine to target a range of emerging biological threats. Heat is showcasing a poster presentation highlighting RapidVax at the World Vaccine & Immunotherapy Congress West Coast and World Antiviral Congress, November 30 to December 2, 2021. RapidVax is designed to enable an accelerated response to a wide variety of infectious agents by providing a flexible "plug and play" vaccine platform that can be stockpiled in advance, and then rapidly customized, manufactured, and deployed to address imminent and future biological threats. This platform has the potential to shorten the timelines needed to develop and test novel vaccines against emerging infectious agents. Jeff Wolf, Chief Executive Officer of Heat, commented, "We are excited to unveil RapidVax, a potentially disruptive approach that leverages our vast experience developing our gp96 platform in both cancer and infectious disease. Heat has treated over 250 patients using its gp96 platform in multiple oncology clinical trials. Furthermore, our gp96-based cellular vaccines demonstrated prophylactic protection in mice and primate models against a range of infectious threat agents, including malaria, HIV/SIV, Zika and SARS-CoV-2 in multiple DOD and NIH-funded studies. The emergence of COVID-19 variants, such as Omicron, further highlights the urgent need for a novel cellular vaccine platform designed to provide a rapid, safe, and effective response to biological threats. We also look forward to leveraging the relationships, experience, and knowledge across our Biothreat Advisory Board as we advance the RapidVax platform."

07:33 EST NextEra Energy to sell 50% stake in renewables project to third party - NextEra Energy (NEE) announced that a subsidiary of NextEra Energy Resources, LLC has entered into an agreement to sell a 50% non-controlling interest in an approximately 2,520 megawatt portfolio of long-term contracted renewables assets to the Ontario Teachers' Pension Plan Board. The remaining 50% interest in the portfolio is under an agreement to be sold by NextEra Energy Resources to NextEra Energy Partners, LP (NEP) pursuant to a purchase and sale agreement executed on Oct. 21, 2021 between a subsidiary of NEP and a subsidiary of NextEra Energy Resources. The sale proceeds are expected to be redeployed into new wind, solar and battery storage growth opportunities, including NextEra Energy Resources' more than 18,000-MW renewables and storage backlog. This attractive capital recycling opportunity provides significant value to NextEra Energy Resources and highlights the value of its renewables development platform. Over the operating life of the assets in the portfolio, NextEra Energy Resources is also expected to receive ongoing annual fee income of approximately $16M in year one and escalating thereafter for operations, maintenance and management services, and the transaction is expected to be accretive to earnings and generate an overall improvement in net present value for NextEra Energy shareholders.

07:32 EST Cummins invests in Sion Power to develop lithium metal technology - Cummins has entered into an agreement with Sion Power, a developer of high-energy rechargeable battery technology, to design and supply battery cells based on their proprietary lithium metal technology for commercial vehicle applications. In connection with the agreement, Cummins has made an investment in Sion Power. The investment provides Cummins a minority stake in Sion Power, allows Sion Power to further develop their lithium metal technology for the commercial vehicle market, and positions both companies for success in the future commercialization of the technology. Under the agreement, Sion Power will engage in a multi-year development program to design and supply large-format lithium metal battery cells for use in Cummins battery packs. The batteries developed by Cummins will be integrated in its electric powertrains for commercial vehicles.

07:19 EST Dorel Home closes Notio Living acquisition for $19M - Dorel Industries announced it has completed its previously-announced acquisition of Notio Living. Dorel Home, a segment of Dorel Industries, is buying the Danish-based company for approximately $19M. Notio Living markets thousands of products sourced from around the world, has been in the home furnishings business for 25 years and operates throughout Europe with a strong presence in the ecommerce market.

07:17 EST Marimaca Copper reports metallurgical results from variablity testing program - Marimaca Copper is pleased to announce results of the variability test work metallurgical progra for the Company's flagship Marimaca Copper Project, located in northern Chile. The variability test work was completed as a component of the Company's ongoing Phase 5 Metallurgical program and additional associated studies, which are expected to be completed in early Q1 2022. The ongoing 2021 metallurgical campaign is focused on finalizing the metallurgical characterization of the Project to a bankable level and builds on the results from the Phase 4 Metallurgical program. The Variability Program was designed to investigate the variability of the Marimaca ore body by assessing copper recovery, acid consumption and impurity dissolution characteristics within each mineralogical domain. This Program represents an important de-risking milestone for Marimaca by increasing certainty and predictability of the metallurgical response for each ore type and spatially across the deposit, and to refine process design criteria prior to the Feasibility Study targeted for 2022. Highlights: Results from the Variability Program demonstrate uniform metallurgical behaviour within each mineral zone when considering acid consumption and copper recoveries; A total of 412 composites across each of the 5 mineral zones within the Marimaca Mineral Resource were analyzed; Results significantly improve the resolution of the Marimaca geo-metallurgical model and will allow for rigorous modeling of recovery and acid consumption across mine blocks ahead of the planned 2022 Feasibility Study; The Program is a core component of the Company's Phase 5 metallurgical testing program, the second program undertaken since the 2020 Preliminary Economic Assessment, which projected average life of mine metallurgical recoveries in the heap leach of approximately 76%; For the oxide mineral zones, recoveries generally exceeded the solubility ratio and leaching potential of the samples, indicating a potentially larger proportion of the copper is acid soluble and will be recovered in commercial-scale heap leaching; The Variability Program represents a significant de-risking milestone and will form the basis for defining recovery and processing assumptions for Feasibility Study and eventual operational mine plans; MOD infill drilling is underway, and MOD Depth Extension infill drilling is currently being planned.

07:16 EST Talaris Therapeutics announces initiation of Phase 2 clinical trial of FCR001 - Talaris Therapeutics announced the initiation of the company's Phase 2 FREEDOM-3 trial in diffuse cutaneous systemic sclerosis, dcSSc, a severe form of the rare autoimmune disease scleroderma. This trial will explore the safety of the company's investigational allogeneic cell therapy, FCR001, delivered with non-myeloablative conditioning, in these patients, as well as its potential to halt the progression of organ damage or induce clinical remission in individuals with dcSSc. "Currently there are no approved, disease-modifying therapies for dcSSc. While there is encouraging data that suggests that patients with dcSSc could benefit from autologous hematopoietic stem cell transplant, the myeloablative conditioning generally associated with those treatment protocols poses considerable safety risks, and disease recurrence has been observed. Unlike autologous HSCT, which infuses the patient's own cells and requires full myeloablative conditioning to optimize efficacy, our investigational therapy, FCR001, is administered with non-myeloablative conditioning and involves the use of cells from a healthy donor with no genetic predisposition for scleroderma," said Nancy Krieger, M.D., Chief Medical Officer at Talaris. "Positive proof-of-concept data in this trial could support the potential applicability of FCR001 to other severe, systemic autoimmune diseases." FREEDOM-3 is a multicenter, open-label study evaluating the efficacy, safety and tolerability of FCR001, the company's investigational allogeneic cell therapy, in adults with rapidly progressive dcSSc at risk for organ failure. It consists of a one-time treatment administered with non-myeloablative conditioning, after which patients are followed for five years, with a primary analysis on a variety of safety and exploratory efficacy endpoints performed at 24 months.

07:15 EST Intema submits application to become gaming, sports betting operator in Ontario - Intema Solutions is pleased to announce that it has applied to the Alcohol and Gaming Commission of Ontario to become a fully registered operator of Internet gaming and sports betting in Ontario, Canada's largest province. On August 27, 2021, the Canadian government enacted Bill C-218, which gave each of Canada's provincial and territorial governments discretion to conduct and manage single-event sports betting in their respective provinces. Ontario is the first province to accept registration applications from prospective iGaming operators, having published its draft standards for regulated online betting and gaming markets in August, soon after Canada legalized single-event wagering, before releasing the finalized standards last month.

07:13 EST LabCorp offers observed self-collection for COVID-19 PCR testing in 500 PSCs - Labcorp is now offering observed self-collection for COVID-19 PCR testing in more than 500 of its patient service centers nationwide for people without symptoms or known exposure. By mid-December, the company plans to further expand the COVID-19 PCR test collection service to over 1,000 locations. "With upcoming holiday travel and increases in large group gatherings, Labcorp wants to make getting tested for COVID-19 faster, easier and more accessible for the communities it serves"

07:11 EST mCloud Technologies signs agreement with Colliers Macaulay Nicolls - mCloud Technologies announced a three-year agreement with Colliers Macaulay Nicolls, an appointed agent of Slate Asset Management, to deploy mCloud's AssetCare solution for HVAC and indoor air quality, or IAQ, at Life Plaza, one of Slate's premier office towers in downtown Calgary. The initial subscription term for this agreement becomes effective at the completion of AssetCare installation and is set to renew in November 2025. This AssetCare solution represents mCloud's largest IAQ deployment to date, providing clean air and energy efficiency improvements to an 18-floor office tower spanning 235,000 square feet across 35 cloud-connected zones.

07:10 EST Olema Oncology announces first clinical data on OP-1250 - Olema Pharmaceuticals announced the first clinical data from the Phase 1 dose-escalation portion of the ongoing Phase 1/2 clinical trial of OP-1250, a complete estrogen receptor, ER, antagonist, CERAN, and a selective ER degrader, SERD, in development for the treatment of metastatic breast cancer and other women's cancers. These initial data provide strong proof-of-concept for OP-1250 as a once-daily oral monotherapy in women with recurrent, locally advanced or metastatic ER+ / HER2- breast cancer and demonstrate OP-1250's potential to become a best-in-class endocrine therapy. Three partial responses and robust target lesion reduction up to 100% were observed in a heavily pretreated patient population. Interim Results from Phase 1a Dose Escalation of OP-1250 as a Monotherapy: Pharmacokinetics , safety, tolerability, and anti-tumor activity of once-daily OP-1250 monotherapy were evaluated in the open-label, dose-escalation portion of the ongoing Phase 1/2 clinical trial. As of November 1, 2021, a total of 41 patients with recurrent, locally advanced or metastatic ER+ / HER2- breast cancer were enrolled across 7 dose cohorts. Overall, patients received a median of 3 prior lines of anti-cancer therapy and 2 prior lines of endocrine therapy in advanced settings. Of 39 patients whose circulating tumor DNA was assessed, ESR1 mutations were detected in 49% at baseline. Pharmacokinetic analyses demonstrated dose-proportional increases in OP-1250 exposures across all evaluated doses, high oral bioavailability and steady-state plasma levels with minimal peak-to-trough variability. OP-1250 was generally well tolerated, and no dose-limiting toxicities were reported at any of the seven dose levels studied. A maximum tolerated dose was not reached. The majority of reported adverse events were grade 1 or 2 at all dose levels, and the most common treatment-related adverse events as assessed by study investigator were nausea, fatigue, vomiting and headache. Three partial responses were observed among 24 efficacy-evaluable patients, including 2 confirmed partial responses and 1 unconfirmed partial response in a patient with robust target lesion reduction of 100%, but whose response remained unconfirmed due to progressive disease with a new lesion appearing at a follow-up visit. Four response-eligible patients had target lesion reductions of greater than 30%. Across all doses, the ORR was 8% and the CBR was 29%. For the dose levels within the RP2D range, the ORR was 17% and the CBR was 46%. As of the data cut-off date, 32% of patients remained on treatment with efficacy data continuing to mature, including both patients with confirmed partial responses. Anticipated Milestones: Based on these promising data, Olema is rapidly advancing OP-1250's clinical development program with a number of anticipated program milestones. Phase 1b dose expansion is ongoing at two dose levels and is expected to enroll 15 patients in each cohort. Findings from this stage will help inform selection of the RP2D. Phase 2 efficacy evaluation is expected to initiate in Q1 2022 with approximately 80 patients enrolled across three cohorts. The first Phase 1b combination study with a CDK4/6 inhibitor is expected to initiate in Q1 2022, with additional combination studies with CDK4/6 and PIK3CA inhibitors planned in 2022. A pivotal study for OP-1250 in the metastatic setting is expected to initiate in 2023.

07:10 EST ImmunityBio enters deal with EnGeneIC for COVID-19, cancer treatments - Australian company EnGeneIC has announced a deal with US biotech ImmunityBio, over a ground-breaking approach to both a COVID-19 vaccine and cancer treatment. Early results from a clinical trial in adults indicate that the antibodies generated can neutralize COVID-19 and all of its variants, including Delta. EnGeneIC's patented EDV nanocell technology also targets and effectively kills cancer cells with minimal toxicity, while stimulating an anti-tumour immune response. Phase I and IIa trials in patients with advanced pancreatic cancer is underway, and the FDA recently approved another trial in the US. Under the deal, EnGeneIC will grant ImmunityBio an exclusive, worldwide licence to develop, manufacture and commercialize EDV in combination with its anti-cancer drugs and COVID-19 vaccine. EnGeneIC will also receive upfront payments and fees for future cancer programs. ImmunityBio will build EDV manufacturing facilities in the USA and South Africa, and cover costs associated with clinical trials and regulatory approvals. The companies have agreed to a 50:50 split on net profit from worldwide sales of EDV-based therapeutics.

07:09 EST Comscore names Brian Pugh as Chief Information Officer - Comscore announced that Brian Pugh is taking on the role of Chief Information Officer. Pugh, who joined Comscore in 2007 and has held executive level positions at the company across Data Science, Analytics, and Product Technology, will now be responsible for launching cost effective technology solutions that increase innovation and productivity, for ensuring that Comscore data is secure in a privacy-focused environment, and for ensuring that Comscore services are accredited for ISO security standards and by industry organizations like the Media Rating Council.

07:07 EST Chico's reports Q3 gross margin 40.7% - The third quarter gross margin rate rose to 40.7%, the best third quarter performance since fiscal 2014, driven by higher full-price sales, less promotional activity, strategic inventory management and improved leverage of occupancy costs on higher sales, partially offset by increases in raw materials and freight costs.

07:06 EST iClick Interactive Asia sees FY21 revenue $318M-$338M, consensus $327M - Tha company said, "Based on the information available as of the date of this press release, iClick provides the following outlook for the FY21: Revenue is estimated to be between $318M and $338M; revenue from Enterprise Solutions is estimated to be between $62M-$68M. The above outlook is based on current market conditions and reflects the Company's preliminary estimates of market and operating conditions, expected foreign exchange fluctuation, and customer demand, which are all subject to change."

07:05 EST First Wave BioPharma says DMC recommended enrollment continue in FW-COV trial - First Wave BioPharma announced that an independent data monitoring committee, DMC, has recommended that enrollment continue in Part 2 of the ongoing RESERVOIR Phase 2 trial evaluating FW-COV as a treatment for COVID-19-related gastrointestinal, GI, infections. FW-COV is a proprietary, oral, tablet formulation of micronized niclosamide developed to remove SARS-CoV-2, the virus that causes COVID-19, from the GI tract. The DMC recommendation was based on its review of the safety data collected from the first 25 patients enrolled in Part 2 of the RESERVOIR trial. The review of the data uncovered no safety issues. Part 2 of the study will enroll up to 150 patients. James Sapirstein, President and CEO of First Wave BioPharma, stated, "The DMC's review of interim safety data was very positive with no substantive safety issues documented in the initial 25 patients dosed in Part 2 of the RESERVOIR trial. This news comes at a critical time in the COVID-19 pandemic with the rise of the fast-spreading Omicron variant, declared last week by the World Health Organization as a variant of concern. Because niclosamide targets the entire virus, and not just the spike protein, we believe that FW-COV may prove effective against multiple strains of COVID-19 and may provide an effective therapeutic to help millions of COVID-19 patients overcome the debilitating and often overlooked effect the virus can have on the GI system. Based on current timelines and pacing of enrollment, which is strong, we expect to report topline results from the RESERVOIR trial next year, including an assessment of FW-COV's ability to clear the COVID-19 virus from the GI tract."

07:03 EST Biomica reports results from pre-clinical studies in its IBD program - Biomica, a subsidiary of Evogene, reported positive results from pre-clinical studies in its IBD program. In these studies, Biomica tested its optimized drug candidate BMC333, which consists of four live bacterial strains derived from Biomica's drug candidates BMC321 and BMC322, which had been previously tested as well. Treatment with these drug candidates demonstrated efficacy in several studies in reducing inflammation for the treatment of IBD. IBD includes conditions such as ulcerative colitis and Crohn's disease, which are chronic, debilitating, non-infectious, inflammatory diseases of the digestive tract. The global IBD treatment market size was valued at $19.2B in 2020. The results Biomica is currently reporting follow the evaluation of BMC333 in a DSS-induced colitis model, which demonstrated BMC333's ability to significantly reduce intestinal tissue damage resulting from inflammation. BMC333 attenuated intestinal inflammation as observed in several key parameters such as reduced fecal lipocalin and reduced inflammation observed in histopathological analysis. Moreover, animals treated with BMC333 demonstrated increased survival rates compared to the untreated group.

07:01 EST Chesapeake names Mohit Singh as CFO, effective December 6 - Chesapeake Energy (CHK) announced that Mohit Singh has been appointed Executive Vice President and CFO, effective December 6. For the last six years, Singh has served on the executive leadership team at BPX Energy, the United States onshore subsidiary of BP (BP).

06:56 EST Aecom awarded secondment contract with Qatar's Public Works Authority - AECOM announced that is has been awarded a four-year secondment contract with Ashghal, Qatar's Public Works Authority. Over 200 AECOM professional staff members will work within Ashghal's Roads Projects Department, providing management and oversight of Ashghal's Local Roads and Drainage Program, which is responsible for developing infrastructure that raises the standard of living for all residents. AECOM's secondees will support the further modernization and expansion of Qatar's surface transport network, improving its accessibility, safety and sustainability for all users. Ashghal was established in 2004 to plan, deliver and manage all infrastructure projects in Qatar. Since then, AECOM has supported the delivery of numerous transformational projects, including Orbital Highway, Lusail Expressway and the MoTC Bus Infrastructure Program.

06:52 EST Becton Dickinson issues statement on testing for COVID-19 Omicron variant - Becton Dickinson issued the following statement regarding testing for the COVID-19 Omicron variant of concern. Dave Hickey, president of Life Sciences for BD said, "BD actively monitors new and developing COVID-19 variants of concern to ensure the integrity and performance of our assays. BD has conducted an analysis of the recently identified Omicron variant of concern and we are confident that our rapid antigen and PCR tests for COVID-19 will detect the novel variant. Our analysis of the Omicron variant was conducted using all available genome sequences deposited in the GISAID EpiCoV(TM) database as of Nov. 29, 2021. When live viral samples are made available, BD will perform additional rigorous testing in the laboratory. BD actively monitors all sequenced SARS-CoV-2 isolates worldwide. Our team has evaluated over 3.5 million genomes to monitor for emerging variants. Variants of concern have been tested by BD and our partners and no undetectable variants have been identified. Reliable and widely available testing remains one of the most important measures to mitigate the spread of COVID-19. BD will continue to monitor and verify the performance of its COVID-19 tests to serve its mission of advancing the world of health."

06:48 EST KULR Technology receives $500,000 battery systems order from Lockheed Martin - KULR Technology (KULR) announced the company has received an initial order totaling approximately $500,000 for its passive propagation resistant battery systems from Lockheed Martin (LMT). This initial order is for immediate delivery and is the starting point in the partnership as LMT leverages KULR's technological advancements in PPR energy products for its Advanced Energy Systems.

06:42 EST ImmunoGen reports data from pivotal SORAYA trial - ImmunoGen announced positive top-line data from the pivotal SORAYA trial evaluating the safety and efficacy of mirvetuximab soravtansine, or mirvetuximab, monotherapy in patients with folate receptor alpha, or FRalpha,-high platinum-resistant ovarian cancer who have been previously treated with Avastin, or bevacizumab. SORAYA enrolled 106 patients with a median of three prior lines of therapy; 51% had three prior lines of therapy and 48% had one to two prior lines of therapy. All patients received prior bevacizumab; 48% of patients received a prior PARP inhibitor. As of the data cutoff on November 16 the median follow-up time was 8.1 months. ORR by investigator was 32.4%, including five complete responses, or CRs. ORR by BICR was 31.6%, including five CRs. Responses were observed regardless of prior PARP inhibitor or number of prior lines of therapy. The median DOR is currently 5.9 months. With nearly half of responders continuing on therapy, the duration of response continues to evolve and, with longer follow-up, median DOR could range from 5.7 to just above 7 months. Mirvetuximab was well-tolerated, consistent with the known safety profile seen in more than 700 patients treated in the broader mirvetuximab program. Treatment-related adverse events led to dose reductions in 19% of patients, dose delays in 32% of patients, and discontinuations in 7% of patients. The most common treatment-related adverse events included blurred vision, keratopathy, and nausea.

06:35 EST ImmunoGen reports data from pivotal SORAYA trial - ImmunoGen announced positive top-line data from the pivotal SORAYA trial evaluating the safety and efficacy of mirvetuximab soravtansine, or mirvetuximab, monotherapy in patients with folate receptor alpha, or FRalpha,-high platinum-resistant ovarian cancer who have been previously treated with Avastin, or bevacizumab. "Despite advances in the platinum-sensitive setting, most patients with ovarian cancer eventually develop platinum-resistant disease, for which there are limited treatment options, especially for those patients who have previously received bevacizumab," said Robert Coleman, Chief Scientific Officer of US Oncology Research and SORAYA Co-Principal Investigator. "Data from SORAYA have the potential to redefine the standard of care for patients with FRalpha-high platinum-resistant ovarian cancer, as this trial has demonstrated that mirvetuximab delivers clinically meaningful benefit in this setting, with significant and durable responses and a favorable tolerability profile." SORAYA is a single-arm study of mirvetuximab in patients with platinum-resistant ovarian cancer whose tumors express high levels of FRalpha and who have been treated with up to three prior regimens.

06:32 EST Apogee Enterprises targets ROIC of over 12% in three years - Apogee Enterprises will host its 2021 Investor Day, which will include presentations by CEO Ty Silberhorn, and other members of the executive leadership team. During the presentations, Apogee's leadership team will discuss their strategic framework for driving profitable growth and improving return on invested capital over the next three years. The company is also announcing new three-year financial goals, which include: Return on invested capital, or ROIC, greater than 12%; operating margin greater than 10%; and revenue growth greater than 1.2 times the growth of the non-residential construction market

06:27 EST AstraZeneca's sNDA for Lynparza accepted and granted priority review by FDA - The company states: "AstraZeneca's (AZN) supplemental New Drug Application, or sNDA, for Lynparza, or olaparib, has been accepted and granted Priority Review in the US for the adjuvant treatment of patients with BRCA-mutated HER2-negative high-risk early breast cancer who have already been treated with chemotherapy either before or after surgery. Lynparza is being jointly developed and commercialised by AstraZeneca and MSD (MRK). The Prescription Drug User Fee Act date, the FDA action date for their regulatory decision, is during the first quarter of 2022. The sNDA was based on results from the OlympiA Phase III trial presented during the 2021 American Society of Clinical Oncology Annual Meeting and simultaneously published in The New England Journal of Medicine. These results showed Lynparza demonstrated a statistically significant and clinically meaningful improvement in invasive disease-free survival, reducing the risk of invasive breast cancer recurrence, second cancers or death by 42% versus placebo. The safety and tolerability profile of Lynparza in this trial was in line with that observed in prior clinical trials." Reference Link

06:04 EST Athersys announces peer-reviewed publication of data from MUST-ARDS trial - Athersys announced that a manuscript reporting data from the Company's MUST-ARDS clinical trial have been published in the peer-reviewed journal Intensive Care Medicine. MUST-ARDS was a randomized, double-blind placebo-controlled Phase 1/2 trial evaluating the safety and efficacy of MultiStem, or invimestrocel, cell therapy in patients with acute respiratory distress syndrome, or ARDS. Enrolling patients at 12 intensive care units in the U.K. and the U.S., the study confirmed that intravenous administration of MultiStem cell therapy was well-tolerated among critically ill patients early in the course of moderate to severe ARDS.

06:02 EST Fennec receives CRL from FDA regarding NDA for PEDMARK - Fennec Pharmaceuticals announced that it received a Complete Response Letter on November 29 from the U.S. FDA, after the PDUFA target action date of November 27, regarding its New Drug Application for PEDMARK for intravenous administration for the prevention of ototoxicity associated with cisplatin chemotherapy in pediatric patients greater than or equal to 1 month to 18 years of age with localized, non-metastatic, solid tumors. The CRL was issued as a result of identified manufacturing deficiencies which need to be satisfactorily resolved before the Pedmark NDA can be approved. Fennec plans to request a Type A meeting with the FDA to discuss these deficiencies and other matters described in the CRL, as well as the steps required for the resubmission of the NDA for PEDMARK. "We are steadfast in our commitment to reducing the risk of life-long hearing loss for children and young adults receiving cisplatin chemotherapy who currently have no approved therapies for this devastating condition," said Rosty Raykov, chief executive officer of Fennec Pharmaceuticals. "We will work closely with our current manufacturer as well as the FDA to fully address the issues raised in the letter. In addition, we continue to advance our second drug product manufacturing facility."

05:48 EST Taiho exercises option for domvanalimab, AB308 from Arcus Biosciences - Arcus Biosciences and Taiho Pharmaceutical announced that Taiho exercised its option for anti-TIGIT antibodies domvanalimab and AB308 from Arcus Biosciences, in Japan and certain other territories in Asia. This option exercise is based on an option and license agreement between Taiho and Arcus contracted in September 2017. Taiho has already obtained exclusive rights to etrumadenant, an adenosine A2a/A2b receptor antagonist, and zimberelimab, an anti-PD-1 monoclonal antibody. This is the third option exercise to an Arcus program. In exchange for the exclusive license, Taiho will make an option exercise payment, as well as additional payments upon achievement of clinical, regulatory and commercialization milestones, and, if any products from the program are approved, will pay royalties on net sales of such products. Domvanalimab is being developed primarily as a combination therapy with anti-PDx checkpoint inhibitors. The Phase 2 and Phase 3 trials of domvanalimab in combination with zimberelimab are currently being conducted by Arcus in first-line metastatic PD-L1 50% non-small cell lung cancer. A Phase 3 trial of domvanalimab in combination with durvalumab is being initiated in Stage III non-small cell lung cancer. Development in other cancer types is also being planned.

05:39 EST Mersana Therapeutics, Synaffix to expand license agreement - Synaffix announced the expansion of its license agreement with Mersana Therapeutics. Under the expanded license agreement, Mersana will expand its access to Synaffix's GlycoConnect site-specific ADC bioconjugation technology for six additional ADC targets. The license rights granted to Mersana are tied to specific ADC targets to be selected and provide non-exclusive access to deploy GlycoConnect site-specific ADC bioconjugation technology against the specified targets. Under the expanded deal, Synaffix is eligible to receive upfront and milestone payments on a per-target basis with a total potential deal value exceeding $1B plus royalties. This builds on the relationship between the two companies announced in 2019.

05:34 EST Boqii enters partnership with Evetsoft Pet Hospital Management Software - Boqii announced a strategic partnership with Evetsoft Pet Hospital Management Software, a pet hospital SAAS solutions company. Together, Boqii and Evetsoft, will launch an online procurement platform tailored for streamlining the procurement process of pet hospitals and clinics.

05:32 EST Expro secures four subsea well access contracts in South East Asia, Australia - Expro has secured four significant subsea well access contracts in South East Asia and Australia worth in excess of $50M. The company has won two contracts in Australia and two in Malaysia. In Australia, Expro has been awarded a multi-million dollar contract for the abandonment of 18 subsea wells and the removal of open water production trees. The project will require Expro to deliver an integrated subsea solution, including its industry-leading Intervention Riser System, or IRS, to access the wells and undertake plug and abandonment work. Also in Australia, Expro has been commissioned to deliver an integrated program for a new subsea development. The major contract will include the delivery of a complete subsea completion landing string package and a bespoke high-rate surface well test system. In Malaysia, Expro has been awarded a seven-figure contract for the provision of large bore electro hydraulic subsea landing string equipment for a new subsea deepwater campaign. Expro was selected due to its outstanding operational performance on similar campaigns in the area during 2019 and 2020. Also in Malaysia, Shell has awarded Expro a substantial contract for the provision of a subsea landing string integrated package for the Gumusut-Kakap deepwater field. The contract is for a fixed scope of work on four development wells.

05:26 EST Cnooc to deregister with SEC, terminate reporting obligations - Cnooc announced that the company intends to deregister with the United States Securities and Exchange Commission and terminate reporting obligations under the U.S. Securities Exchange Act of 1934, as amended. The New York Stock Exchange filed Form 25 with the SEC on October 12 and the delisting of the company's American depository shares became effective following the close of the market in New York on October 22.

05:21 EST Baozun announces new $50M share repurchase plan - Baozun announced that, as the company has already completed its $125M share repurchase program announced on May 18, in addition to the said share repurchase program, its board of directors has authorized a new share repurchase program under which the company may repurchase up to $50M worth of its outstanding American depositary shares, each representing three Class A ordinary shares, and/or Class A ordinary shares over the next 12 months starting from November 30.

05:07 EST JinkoSolar sees FY21 total shipments 22.8 GW-24.3 GW - The company said, "JinkoSolar expects its annual mono wafer, solar cell and solar module production capacity to reach 32.5 GW, 24 GW (including 940 MW N-type cells) and 45 GW, respectively, by the end of 2021."